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M a r i s s a  K a n e  
 
Unlike normal cells, cancer cells can grow in low oxygen (hypoxic) environments. 
Changes in relative oxygen concentration can alter gene expression in tumors to allow for 
their selective growth. The result of such changes allows the tumor to adapt its cellular 
metabolism and promote tumor progression. Most notably, hypoxic conditions induce 
expression of the transcription factor hypoxia inducible factor 1 (HIF-1).  HIF-1 is thought 
to directly affect glucose transporter 1 (GLUT1) expression levels in hypoxic conditions. 
This study sought to determine the relationship between HIF-1 and GLUT1 expression 
levels within normoxic and hypoxic environments utilizing an in-vitro GBM model. The data 
accumulated in this study determined that hypoxia correlates with relative expression 
levels of hypoxia inducible factors (HIFs) as well as GLUT1. HIF-1 and GLUT1 appear to 
have different expression levels in fibroblast cells than in GBM cells, solidifying that HIF-1 
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I n t r o d u c t i o n  t o  G l i o b l a s t o m a  ( G B M )  
 
 
The current standard of care for Glioblastoma multiforme tumors (GBM) rarely 
cures the patient. The typical survival time for 75% of patients is 18 months after their 
diagnosis and less than 10% of patients survive longer than 5 years past diagnosis, despite 
severe surgical debulking procedures, chemotherapy, and radiation treatment regimens 
(Mansour, Fields, Macomson, & Rixe, 2014)(Ali, 2013).   
This low survival rate is mostly due to the ability of these tumors to recur quickly 
and aggressively.  It is thought that within the tumor there are distinct subpopulations of 
cells that are stem-like in their behavior (Singh et al., 2003).  These stem-like cells give the 
tumor self-renewing properties and therefore help the tumor to grow back from only a few 
cells remaining after treatment (Hjelmeland et al., 2011, p. 829).  GBMs are typically hard 
to surgically remove because the bulk of the tumor can be diffuse and often lies adjacent to 
important fiber tracts, blood vessels, and other structures in the brain (Park et al., 2010).  
Debulking surgeries reduce the size of the bulk tumor but fail to target specific 
subpopulations of cells within the tumor, such as the stem-like cells that can help the tumor 
grow back.  The location of the tumor and the inherent cellular and genetic heterogeneity 
  2 
within the tumor can influence how aggressive the surgeon will be when removing the 
tumor (Y. Wang & Jiang, 2013).  
In addition to surgery, also included in the standard of care regimen are radiation 
and chemotherapy.  Surgery targets the bulk of the GBM, but leaves behind as much of the 
tumor as is needed to preserve as much brain function as possible (Park et al., 2010).  
Radiation and chemotherapy specifically target fast-growing cells that inherently comprise 
the bulk of the tumor mass, but these treatments have variable effectiveness because they 
fail to target the characteristic hypoxic microenvironment within the tumor.  The hypoxic 
tumor microenvironment promotes tumor aggression and stem cell formation and confers 
treatment resistance (Covello et al., 2006).  These methods are inherently not effective at 
killing the slow growing cells in the GBM and therefore are leaving the cancerous stem-like 
cell population mostly unharmed.  However, all stem cells can’t just be targeted to kill the 
GSCs, as there is the issue of having undesired effects by killing healthy neural stem cells in 
addition to the malignant stem cells which would further impair the healing process 
(Lawson et al., 2007). 
The cellular, genetic, and epigenetic heterogeneity of GBMs makes designing 
targeted treatments difficult.   One example of a mutation present in some GBM patients in 
in the enzyme IDH1 (isocitrate dehydrogenase 1).  IDH1 is a mitochondrial enzyme that, 
when mutated, has a normal loss in function and leads to the accumulation of 2-
hydroxyglutarate (2-HG) (Turkalp, Karamchandani, & Das, 2014) which has been shown to 
inhibit the enzymatic function of several histone and DNA demethylases.  This leads to 
uncorrected methylation on genes whose expression, when altered, can confer 
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tumorigenesis (Xiang & Zhi-Qiang, 2015).  So indirectly, IDH1 accumulation confers tumor 
aggression and its expression is characteristic in secondary GBM.  IDH1 acts as a prognostic 
marker in GBM (Parsons et al., 2008) since its expression correlates with tumor grade 
(Kickingereder et al., 2015).   Overall, patients have genetic or epigenetic mutations in 
combinations that are often unique to their tumor, and often these mutations prevent 
treatments such as chemotherapy, radiation, or surgery from curing the patient.  
Consequently, there is a need for individualized treatments based on the patient’s tumor 
genetic profile.   
In addition to genetic mutations present in GBMs, epigenetic changes are also 
prevalent and preclude certain chemotherapy treatments from eradicating the tumor.  
Epigenetic changes are evident by methylation or demethylation of promoter or enhancer 
regions of DNA, which can lead to gene overexpression or gene silencing.  An example of 
this is in the gene MGMT (O6-methylguanine–DNA methyltransferase).   The MGMT gene 
codes for a DNA repair protein that removes alkyl groups that chemotherapy drugs, such as 
Temozolomide (TMZ), add to tumor DNA to kill cells (Esteller et al., 2000).  The alkyl 
groups that TMZ adds to the tumor DNA, halts cell replication followed by apoptosis in the 
affected cell (Hegi et al., 2004)(Ochs & Kaina, 2000)(L. Liu, Markowitz, & Gerson, 1996).  
The potential effects of TMZ on the tumor DNA of a person with normal MGMT will be 
unaffected by the chemotherapy drug because their functional MGMT protein will just fix 
the DNA alkylation that the TMZ caused.  Therefore, when the MGMT promoter is 
methylated and its expression is silenced, the tumor becomes more susceptible to 
chemotherapy alkylating drugs, such as TMZ, and when combined with radiotherapy leads 
to longer overall survival for the patient (Hegi et al., 2005).  Therefore, the gene MGMT is a 
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common prognostic factor that surgeons and oncologists use to design treatments that will 
be as effective as possible for the patient (Hegi et al., 2005).   
In addition to the challenges presented by the cellular, genetic, and epigenetic 
heterogeneity of the tumor, aspects of the general biology of the brain leads to challenges, 
specifically the blood brain barrier.  The presence of the blood brain barrier (BBB) makes it 
difficult to treat GBM, as it severely limits what can pass into the brain.  The BBB is a 
neuroprotective barrier system for the capillaries of the brain and is mostly comprised of 
endothelial cells connected by tight junctions (Persidsky, Ramirez, Haorah, & Kanmogne, 
2006) and acts to prevent toxins and pathogens from reaching the brain. Because of the 
challenges in permeating the BBB, drug design is difficult and existing treatments for other 
cancers might not be a viable option for a GBM patient (Juillerat-Jeanneret, 2008).  
However, nanotechnology appears to be growing more effective at treating GBM by 
exploiting the presence of LDL receptors on the endothelial cells (Dehouck, Dehouck, 
Fruchart, & Cecchelli, 1994) and are also more highly expressed in GBM (Nikanjam, Gibbs, 
Hunt, Budinger, & Forte, 2007).   
 
H y p o x i a  a n d  t h e  T u m o r  M i c r o e n v i r o n m e n t  
 
 
Abnormal physiology and abnormal location of cells contribute to the characteristic 
uncontrolled growth of cancer.  The cancer cells proliferate with very few stop mechanisms 
and turn off remaining genes that, when normally translated to proteins, would act to 
prevent abnormal cell growth.  Resulting from the constant growth is an increased 
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metabolism (discussed more below) and a growing distance between cancer cells and 
proper vasculature.  Although cancer cells are abnormal in terms of their growth, 
metabolism, and other properties, they have need to maintain some semblance of normal 
cell physiology, including proper nutrient delivery and waste management.  Although the 
cancer cells try to mimic some of the normal physiological processes such as angiogenesis 
(blood vessel formation), this ultimately fails and there is still variably lower oxygen in 
many parts of the tumor, usually in a gradient-like manner.  Consequently, the typical 
microenvironment of bulk tumors is generally hypoxic (lower than normal oxygen), low 
pH, and nutrient deficient (Pouysségur, Dayan, & Mazure, 2006)(Pouysségur, Dayan, & 
Mazure, 2006) since they don’t have proper vasculature.  
Cancer cells have the unique ability to survive under hypoxic conditions (Hsu & 
Sabatini, 2008).  Hypoxia has been characterized as a main reason for the poor prognosis 
for GBM patients (G. L. Semenza, 2002) and has been implicated in tumor cell proliferation, 
survival, cell migration, invasion, and treatment resistance (G. L. Semenza, 2002)(Bar, Lin, 
Mahairaki, Matsui, & Eberhart, 2010)(Joseph et al., 2015).  Hypoxic conditions have been 
shown to induce changes in a myriad of genes, which lead to numerous new physiological 
changes that distinguish cancer from normal tissue.  Resulting from the hypoxic 
microenvironment itself, and the genetic changes indirectly elicited by hypoxia, treatments 
are largely ineffective for GBMs (P. Wang et al., 2017, p. 1)(Mohyeldin, Garzon-Muvdi, & 
Quinones-Hinojosa, 2010)(Chiche, Ricci, & Pouysségur, 2013)(Chiche, Ricci, & Pouysségur, 
2013).  Some of the characteristic aggressiveness of GBMs derives from the heterogeneity of 
the cells within the tumor, as well as from genetic and epigenetic changes (Liberti & 
Locasale, 2016a).   
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A subpopulation of cells in GBM tumors, cancerous glioma stem cells, (GSCs) share 
the self-renewing properties of normal stem cells, but the malignancy and aberrant 
signaling of cancer cells (Singh et al., 2003)(Qiu, Fang, Luo, & Ouyang, 2015).  These tumor-
initiating cells or cancer stem cells (CSCs) exist within the tumor and provide it with the 
ability to resist treatment and to lie dormant until the cancer stem cells eventually 
recapitulate the tumor.  CSCs might originate from non-stem cancer cells that 
dedifferentiate due to hypoxic conditions within the tumor microenvironment (P. Wang et 
al., 2017).  The alleged CSCs or tumor-initiating cells have displayed the ability to 
recapitulate a tumor, despite only comprising a small percentage of the overall tumor mass 
(P. Wang et al., 2017)(Singh et al., 2003).  A recent study found that the glioma stem cell 
(GSC) subpopulation led to tumor aggressiveness, but also that GSCs are dedifferentiated 
from differentiated glioma cells (P. Wang et al., 2017).  This highlights the debate about the 
origin of GSCs, whether they derive from malignant neural stem cells or whether they are 
differentiated glioblastoma cells that dedifferentiated into GSCs.  
Both cancer stem cells and genetic variety within the tumor are implicated in the 
scheme of tumor development (Liberti & Locasale, 2016b).  The tumor microenvironment 
selects for the growth of different cell populations within GBMs, however, it seems intuitive 
that the opposite is true as well. The heterogeneity comprising the GBM microenvironment 
results in different growing conditions for cells and leads to genotypic and phenotypic 
variability within the tumor, which then leads to difficulties in making targeted GBM 
treatments (Covello et al., 2006)(Lawson et al., 2007)(Hegi et al., 2005)(Gao, Shen, Jin, 
Miao, & Qiu, 2016).  Overall, there appears to be a relationship between the types of cells 
comprising these GBM subpopulations, the relative oxygen conditions and the vascularity 
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of the tumor microenvironment, which is discussed more in-depth in future sections.  In 
addition to the advantages directly conferred to cancer stem cells by hypoxia, there are 
numerous hypoxia induced downstream changes that elicit genetic changes within GBMs 
that confer other advantages for the tumor (Liberti & Locasale, 2016b).  These genetic 
changes within the tumor are the foundation for the characteristic ‘hallmark’ changes seen 
in cancer progression: such as angiogenesis, immune evasion, resistance to apoptosis, 
dormancy from cancer stem cells, inflammation, metastasis, resistance to therapies, and 
metabolic reprogramming (Hanahan & Weinberg, 2011)(Ravi et al., 2002), which are 
discussed again below.  As described above, epigenetic changes within tumors also confer 
different factors that affect the prognosis of the patient (Hegi et al., 2005).  
Due to the perpetual and uncontrolled growth of cancer cells, tumors quickly 
outgrow their available vascular supply.  As tumors grow, proper vasculature is not created 
quickly enough to adequately provide for the metabolic needs of the tumor cells; most 
notably, oxygen delivery. Oxygen must diffuse over long distances to reach the portions of 
the tumor that lies farthest from the vascular supply.  This mismatch of O2 consumption 
and delivery in certain areas of the tumor leads to a gradient of local decreased partial 
pressure of oxygen, which is referred to as hypoxia (Denko, 2008).  Hypoxia is the relative 
deprivation of oxygen and a complete deprivation is called anoxia (West, 1977).  Hypoxia 
has been shown to lead to the expression of genes that lead to some of the ‘hallmark’ 
changes seen in cancer, including: sustained proliferative signaling, evasion of growth 
suppressors, activation of invasion and metastasis mechanisms, replicative immortality, 
induction of angiogenesis, and resistance to cell death (Heikkilä, Pasanen, Kivirikko, & 
Myllyharju, 2011)(Heikkilä, Pasanen, Kivirikko, & Myllyharju, 2011).  There are also several 
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‘emerging hallmarks’ or major themes underlying cancer progression that are now being 
studied: reprogramming energy metabolism and evasion of immune destruction (Hanahan 
& Weinberg, 2011)(Ravi et al., 2002).  
Cancer cells, like normal cells, require nutrients and mechanisms to transport 
wastes. To accommodate the needs of the growing tumor, cancer cells can initiate the 
process of angiogenesis to create new blood vessels (Hanahan & Weinberg, 2011).  
However, blood vessel formation in cancer is very different from normal vessel formation.  
Normal physiological processes, such as in embryogenesis, wound healing, or female 
reproductive cycling, characteristically have new blood vessel formation. Angiogenesis is 
the short-lived process of forming new vessels in developing and normal tissues; the 
vessels are organized and lined with endothelial cells without gaps between them (Ferrara, 
2010).  In contrast, tumor neovasculature is aberrant and is accentuated in hypoxia 
(Ferrara, 2010)(Hanahan & Weinberg, 2011) and this can also lead to uneven drug 
distribution when drugs even make it this far into the tumor.  The process of cancer-
induced angiogenesis is discussed more in depth in later sections.  
 
 
I n t r o d u c t i o n  t o  t h e  W a r b u r g  E f f e c t  
 
 
As mentioned above, angiogenesis occurs in the tumor to attempt to fulfill the vast 
metabolic demand of the proliferating cancer cells.  However, the process does not succeed 
at fully oxygenating the tumor and this causes changes in the relative oxygen concentration 
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in the tumor microenvironment.  Normal tissues anaerobically process glucose to pyruvate 
using glycolysis in the cytosol before further breakdown to carbon dioxide in the 
mitochondria, which creates 36 ATP from each glucose molecule in the aerobic process 
called oxidative phosphorylation (Warburg & others, 1956a).  Normally, glycolysis is not 
the primary process used for the bulk of energy metabolism, as it is far less energy efficient 
than normal mitochondrial oxidative phosphorylation.  Overall, glycolysis in the cytoplasm 
accounts for only about 10% of the ATP generation needed for a normal cell, with the other 
90% being generated from pyruvate processed by oxidative phosphorylation in the 
mitochondria of the cell (DeBerardinis et al., 2007).  
Despite the greater metabolic need of actively proliferating cancer cell 
subpopulations, nearly 50% of a cancer cell’s energy is produced by glycolysis (Denko, 
2008).  Cancer cells preferentially use glycolysis followed by lactic acid fermentation in the 
cytosol, despite its inefficiency at creating ATP per glucose molecule: which is reportedly 
~18-fold less efficient at making ATP than is mitochondrial oxidative phosphorylation 
(Denko, 2008).  In the 1920s, Otto Warburg characterized this phenomenon and termed it 
aerobic glycolysis, which is now also referred to as the Warburg Effect (Warburg & others, 
1956b)(Hsu & Sabatini, 2008)(Warburg, Wein House, Burk, & Schade, 1956).  The inner 
workings of the Warburg Effect remain elusive in cancer cell metabolism studies today, but 
there seems to be a consensus that this metabolic shift to glycolysis is advantageous to the 
tumor.  In 1929, Crabtree confirmed Warburg’s findings of ‘aerobic glycolysis’, but also 
found fermentation occurring.  Warburg later proposed that dysfunctional mitochondria 
were to blame, but his theory was not very popular until signaling cascades were better 
understood, as many of the enzymes used in mitochondrial metabolic processes are 
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downregulated by hypoxia induced signaling changes (Denko, 2008)(Papandreou, Cairns, 
Fontana, Lim, & Denko, 2006).  Accordingly, some experts believe that both mitochondria 
and aberrant aerobic glycolysis play a role in Warburg’s phenomenon.  Although aerobic 
glycolysis in the cytosol is less efficient at generating ATP per molecule of glucose than 
oxidative phosphorylation in the mitochondria, lactate production derived from glucose 
metabolism occurs 10-100 times faster than glucose oxidation via the mitochondria (Figure 
4) (Vander Heiden, 2009)(Shestov et al., 2014). This difference in the speed of glucose 
breakdown and subsequent rapid ATP production could account for why aerobic glycolysis 
is used preferentially to mitochondrial oxidative phosphorylation.  
Many of the genetic and phenotypic changes described by the Warburg Effect can be 
attributed to the hypoxic conditions that occur within the tumor microenvironment, 
specifically by the family of transcription factors called hypoxia-inducible factors (HIFs) 
(Figures 1) (Ruan, Song, & Ouyang, 2009)(Hsu & Sabatini, 2008). Hypoxia leads to induced 
expression of HIFs, which have many downstream target genes: most notably, VEGF and 
GLUT1 (Fukumura et al., 2001).   Glucose transporter 1 (GLUT1) facilitates the uptake of 
glucose into cells and is overexpressed in GBMs.  GLUT1 overexpression allows for higher 
rates of aerobic glycolysis which indirectly creates an acidic tumor microenvironment 
(Liberti & Locasale, 2016b) due to the excess of lactate from fermentation (Figure 4).  
However, this pH drop is short-lived because monocarboxylate transporter (MCTs) 
expression increases to transport the lactate out of the cell. However, the lactate does not 
all leave the cell despite the addition of more MCTs; not all the lactate can be transported 
away from the cell due to the poor vasculature constructed via tumor induced angiogenesis 
(Gillies, Robey, & Gatenby, 2008)(Newell, Franchi, Pouyssegur, & Tannock, 1993).  
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Regardless, this decrease in pH confers advantages to the tumor, such as increasing 
VEGF expression (Fukumura et al., 2001), the main driver of angiogenesis: a process that 
facilitates more opportunities for the delivery of oxygen and other nutrients, as well as 
waste removal.  Additionally, new vasculature creates a way for cancer cells to get 
transported to other areas of the body, which drives tumor invasion and metastasis (Sun et 
al., 2007).  The preference for quick glucose metabolism, rather than more efficient 
metabolism, results in competition for resources between tumor cells and other cells in the 
vicinity such as tumor-infiltrating lymphocytes and stromal cells (Chang et al., 2015)(Ho et 
al., 2015). Therefore, hypoxia and the induced expression of hypoxia inducible factors play 




T i s s u e  D i s t r i b u t i o n  o f  H y p o x i a  I n d u c i b l e  F a c t o r s  ( H I F s )  
 
Hypoxia inducible factors are a family of transcription factors that respond to 
relative changes in oxygen or in response to oncogenic signaling mechanisms (Smith, 
Robbins, & Ratcliffe, 2008)(Wilkins, Abboud, Hancock, & Schofield, 2016)(Y. Liu et al., 
2009a, p. -3).  Three paralogs of the hypoxia-inducible transcription factor family have 
been identified in mammals: HIFs-1, 2, and 3 (Figure 2) (Tanaka, Wiesener, Bernhardt, 
Eckardt, & Warnecke, 2009).  HIFs are a heterodimeric transcription factors that possess 
either HIF-1 or HIF-2 as the oxygen sensitive subunit and a constitutively expressed HIF 
beta subunit (Figure 3) (Denko, 2008).  The expression of both HIF-1 and HIF-2 have been 
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implicated in several normal physiological processes such as erythropoiesis and 
angiogenesis (C.-L. Chen, Chu, Su, Huang, & Lee, 2010, p. 57).  The HIF-1α subunit is 
ubiquitously expressed throughout the body, although two groups did not detect HIF-1 
expression in normal brain tissues (Zhong et al., 1999)(Y. Liu et al., 2009a).  However, it 
should be noted that HIF-1 expression is correlated to pathological grade of glioma (Ravi 
et al., 2002).  HIF-1 is stabilized and upregulated in hypoxic conditions, after oncogene 
activation, and/or from tumor suppressor gene inactivation, which leads to downstream 
gene activation (Figure 5).  Loss of function of the tumor suppressor gene p53 upregulates 
HIF-1 expression (Ravi et al., 2002).  Expectedly, higher expression levels of HIF-1 and 
VEGF were seen in the most necrotic and least vascularized areas of the GBM (Chan et al., 
1998).  The correlation with HIF-1, VEGF, and GBM pathological grade indicates that HIF-
1 is likely important in regulating invasion and metastasis.  
In normal tissues, HIF-2α plays a role in the process of erythropoiesis. Generally, the 
main actions of HIF-1 or HIF-2 are to mediate the cellular and systemic responses to 
hypoxic conditions in the body, but the expression of each HIF has yet to be fully elucidated 
(Patel & Simon, 2008).  HIF-2α is expressed in certain tissues: vascular endothelial cells, 
neural crest cell derivatives, glial cells (Hu et al., 2006), lung type II pneumocytes (Patel & 
Simon, 2008), liver parenchyma, cardiomyocytes, and interstitial cells in the kidney and 
several other organs (Ruan et al., 2009)(Zhao, Du, Shen, Zheng, & Xu, 2015)(M. S. Wiesener 
et al., 1998)(M. Wiesener, 2003), neuroblastoma (Holmquist-Mengelbier et al., 2006), and 
glioma stem cells (Li et al., 2009). HIF-2α expression has been implicated with several 
types of stem cells , including embryonic stem cells (Covello et al., 2006, p. -4)(Hu et al., 
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2006)(Mohyeldin et al., 2010).  Importantly, HIF-2 makes an ideal therapeutic target 
because GSCs overexpress HIF-2 whereas and normal neural progenitor cells produce 
nearly undetectable levels (Li et al., 2009).  Therefore, since HIF-2 isn’t produced in 
healthy progenitor cells, it seems likely that a therapy aimed at targeting HIF-2 is a viable 
option. By somehow blocking the expression of genes downstream of HIF-2, a cancer 
specific therapy could be made that would potentially have less unwanted cell death and 
therefore fewer unwanted effects for patients.  Contrastingly, since HIF-1 is more 
ubiquitously expressed, it might not be the most suitable HIF available to target only GBM 
and GSCs because it might cause undesired cell death in other tissues.  A third HIF  
isoform, HIF-3α, was discovered in 1998; HIF-3α expression is poorly characterized and 
the role that HIF-3α plays in hypoxia mediated functions is poorly understood.  Overall, less 
is known about HIF-3 expression and regulation than about HIF-1 and HIF-2 (Tanaka 
et al., 2009). 
 
I n d u c t i o n  a n d  R e g u l a t i o n  o f  H I F - 1  a n d  H I F - 2  
 
 
H I F - 1  
 
 
The hypoxia inducible factor proteins HIF-1α and HIF-2α share very similar protein 
domains (Figure 2) and are mainly regulated via their oxygen-dependent domains (ODDs).  
Their shared homology is most apparent in the N-terminal basic Helix-Loop-Helix (bHLH) 
domain which is adjacent to the two Per-ARNT-Sim (PAS) domains: the oxygen-dependent 
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domains characteristic of HIF-1 and HIF-2.  Under hypoxic conditions, the PAS domains 
allow hetero-dimerization and DNA binding to occur; the C-terminal of HIF facilitates 
interactions with coactivators such as CREB binding protein and p300 (Jiang, Zheng, Leung, 
Roe, & Semenza, 1997)(Kallio et al., 1998)(Pugh, O’Rourke, Nagao, Gleadle, & Ratcliffe, 
1997)(Pugh, O’Rourke, Nagao, Gleadle, & Ratcliffe, 1997).  These coactivators facilitate 
transcription by interacting with sequence specific DNA binding proteins and with other 
RNA Polymerase II associated general transcription factors (G. Semenza, 2000).  
Importantly, there are conserved proline sequences within the PAS domains of all HIF-, 
which get targeted for degradation under normoxic conditions (Figure 2)(Heikkilä et al., 
2011)(Heikkilä et al., 2011).  The structure of HIF-3α is similar to alpha subunits of HIF1 
and HIF2, sharing 55% amino acid sequence identity and share similar domain structures 
(Figure 2) (Gu, Moran, Hogenesch, Wartman, & Bradfield, 1998).  
Both HIF- and  mRNAs are found in normal cells and are constitutively 
transcribed and translated into functional proteins. The HIF-1  subunits are constitutively 
active in all oxygen conditions.  However, in normoxic conditions, HIF-1 proteins are 
rapidly degraded and have a typical half-life of five to ten minutes (Chiche et al., 2013, p. 
112) (Qingdong Ke & Costa, 2006, p. 1470) (Cunningham, Candelario, & Li, 2012, p. 411)(Q. 
Ke & Costa, 2006).  Consequently, HIF activation depends mostly on the stability of the 
alpha subunit (G. L. Semenza, 2002).  Additionally, HIF-1 is constitutively overexpressed 
when the von Hippel-Lindau tumor suppressor gene is lost (Y. Liu et al., 2009a, p. -
3)(Huang, Gu, Schau, & Bunn, 1998).  As mentioned earlier, there are highly conserved 
proline sequences in the bHLH and PAS domains of both HIF-1 and 2 proteins that are 
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hydroxylated by the enzyme prolyl hydroxylase (PHD).  Asparagine sequences are 
hydroxylated in the C-terminal protein domain by enzymes called factor inhibiting HIF 
(FIHs).  Additionally, lysine residues in the oxygen dependent degradation domain of HIF 
subunits are acetylated by an acetyltransferase called arrest-defective-1 (ARD1), making it 
more favorable for association with the pVHL ubiquitin-elongin complex (Jeong et al., 
2002).  Jeong et al found that the activity of acetyltransferases is not influenced by oxygen 
conditions and concluded that the ARD1 facilitated acetylation of HIF-1 was irrelevant to 
relevant oxygen levels (Jeong et al., 2002). However, both mRNA and protein ARD1 levels 
were decreased in hypoxia which leads to the conclusion that there might be relatively 
lower levels of acetylated HIF-1 in hypoxia than in normoxia. Overall, all HIF- is 
destabilized by the hydroxylation of its proline, asparagine, and lysine segments: and 
hydroxylation also serves as a recognition signal for ubiquitination (Denko, 2008)(Stiehl et 
al., 2006).  The pVHL complex ubiquitinates HIF-1 subunits thereby targeting it for 
proteasomal degradation (Qingdong Ke & Costa, 2006, p. 1470)(Stickle et al., 2004).  The 
pVHL complex is ubiquitously expressed in many tissues and it is mostly localized to the 
cytoplasm and thus facilitates HIF- degradation to occur in either the nucleus or the 
cytoplasm of normoxic cells (Berra, Roux, Richard, & Pouysségur, 2001)(Berra, Roux, 
Richard, & Pouysségur, 2001)(Groulx & Lee, 2002).   
In hypoxic conditions,  HIF-1 increases in stability and is therefore no longer 
targeted for degradation, thereby increasing functional HIF-1 protein subunits (Denko, 
2008).  Oxygen is a low-affinity substrate for the PHDs and so when oxygen levels decrease, 
PHD mediated hydroxylation decreases.  Additionally, FIHs are inhibited and HIF-1 
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doesn’t get hydroxylated (Denko, 2008); therefore, the inactivation of PHDs and FIHs 
prevents HIF-1 ubiquitination mediated proteasomal degradation (Eales, Hollinshead, & 
Tennant, 2016).  Additionally, HIF-2 has been shown to not be as responsive as HIF-1 to 
PDH-2 and PDH-3 induced degradation (Pasanen et al., 2010).  This method of 
hydroxylation or acetylation-mediated regulation is the primary way HIF-1 gene 
expression is regulated, but there are other processes that modulate HIF-1 activity in 
tumors as well as for HIF-1 post-translational regulation that are not discussed in this 
review (Denko, 2008). In summary, HIF-1 is constitutively expressed, while HIF-1 post-
translational stability is induced by hypoxic conditions (Qingdong Ke & Costa, 2006, p. 
1469) (Denko, 2008).   
In hypoxic conditions, stabilized HIF-1 translocates to the nucleus where it 
dimerizes with HIF-1 (Figure 3) and recruits cofactors such as CPB/p300 (Figure 5) 
(Denko, 2008) (Qingdong Ke & Costa, 2006, p. 1470) which bind to hypoxia-responsive-
elements (HREs) in the enhancer or promoter regions on target DNA sequences (Chiche et 
al., 2013, p. 112)(Denko, 2008)(Pouysségur et al., 2006)(Pouysségur et al., 2006).  In this way, 
HIF-1/ initiates transcription of target genes associated with decreased mitochondrial 
respiration, increased glycolysis, pH regulation, erythropoiesis, apoptosis, survival, 
motility, basement membrane integrity, vasodilation, angiogenesis, and hematopoiesis; 
these HIF target genes are discussed below (Tanaka et al., 2009)(Qingdong Ke & Costa, 
2006, p. 1474) (Chiche, Brahimi-Horn, & Pouysségur, 2010, p. 776)(Chiche, Brahimi-Horn, & 
Pouysségur, 2010, p. 776). The HIF family transcriptionally and post-translationally 
regulates an expansive set of downstream genes that establishes many of the characteristic 
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behaviors of cancer, which makes them a very relevant target to study for future cancer 
therapeutics.  
HIF-1α is the most widely expressed of the HIFs and has been characterized in head 
and neck cancers, ovarian cancer, and oesopharyngeal cancer: all of which have poor 
prognosis and are therapy resistant (Talks et al., 2000).  Another study found 
overexpressed levels of HIF-1 in colon, breast, gastric, lung, skin, pancreatic, prostate, and 
renal carcinomas; HIF-1 overexpression was also correlated with cell proliferation in this 
study (Talks et al., 2000) (Zhong et al., 1999). HIF-1 mRNA expression has also been 
implicated with wound healing (Elson, Ryan, Snow, Johnson, & Arbeit, 2000) which is not 




H I F - 2  
 
Like the HIF-1α/ heterodimeric complex, HIF-2 has an oxygen regulated subunit 
HIF-2α and binds to a HIF-2 complex. HIF-2 expression is characterized in stem cells, 
endothelial cells, as well as in glioma stem cells (Covello et al., 2006).  Some studies have 
shown that HIF-2α has a higher specificity for targeting erythropoiesis, whereas HIF-1 was 
said to specifically target glycolytic enzymes (Pasanen et al., 2010).  Another study found 
that there was higher expression of HIF-2α in high-grade pediatric astrocytoma than in 
low-grade astrocytoma; therefore, HIF-2α might correlate with tumor aggression (Khatua 
et al., n.d.).  These studies indicate overall differential regulation patterns amongst the 
members of the HIF family of transcription factors. Some tissues express higher levels of 
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HIF-1α than HIF-2α and vice versa (Keith & Simon, 2007) and the differential regulation 
also seems to depend of the oxygen concentration. For example, in neuroblastoma samples, 
there were strong expression levels of HIF-2α in well vascularized areas.  Similarly, in-vitro 
neuroblastoma studies at 5% O2, which simulated normal physiological oxygen conditions 
of an end-capillary, found stable expression of HIF-2α protein and expression of VEGF, a 
common downstream HIF-1α target gene, despite low HIF-1α expression levels.  This was 
interesting because HIF-2α induced the expression of the same downstream target as HIF-
1α.  When cultured at 1% O2, there was brief stabilization of HIF-1α whereas HIF-2α 
protein gradually accumulated and led to a more chronic hypoxia mediated response 
(Pasanen et al., 2010).   HIF-2α knockdown reduced neuroblastoma growth in athymic mice 
which supports that HIF-2α expression correlates with clinical stage, and along with high 
VEGF expression, can predict poor prognosis for patients (Holmquist-Mengelbier et al., 
2006)(Pasanen et al., 2010).  More generally, this provides evidence that there is 
differential expression of HIF-1α and HIF-2α at different oxygen levels, even within the 
general classification of a hypoxic environment.  These findings also promote the idea that 
the HIF regulation differs in acute hypoxia as opposed to chronic hypoxia (Pasanen et al., 
2010). There is also evidence that HIF-2α has a larger role in the GSC population, making it 





I n d u c t i o n  a n d  R e g u l a t i o n  o f  H I F - 3   
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The regulation of HIF-3α is not as well characterized as that of HIF-1α and HIF-2α. 
There are various reports categorizing the expression levels of the various HIF-3α 
isoforms. Some groups have reported that HIF-3αv1 (variant 1) mRNA is upregulated by 
hypoxia, while the HIF-3αv4 was downregulated. Another reported that among other splice 
variants, HIF-3αv4 was actually hypoxia inducible (Pasanen et al., 2010).  RNA interference 
experiments also found that HIF-1α and not HIF-2α was responsible for the hypoxia 
inducible nature of HIF-3α variants and these findings were also seen in renal carcinoma 
Caki cells by Tanaka et al in 2009 (Pasanen et al., 2010)(Tanaka et al., 2009) .  
The multiple splice variants of HIF-3α also appear to have differing functions based 
on the tissue they are expressed in.  It is currently unknown whether HIF-3 mediated 
negative regulation of HIF-1 occurs ubiquitously or at all. Other studies have said that the 
roles of HIF-3α variants might be more versatile than just negatively regulating HIF-1α and 
HIF-2α (Heikkilä et al., 2011)(Heikkilä et al., 2011).  More studies are needed to tease out the 
role of HIF-3α/ in general as well as in the context of GBM.  A set of database studies 
predicted that there are three possibly utilized transcription initiation sites on the six 
splice variants and found that hypoxia upregulated expression of all three promoter sites. 
They also found that the promoter expression was mediated exclusively by HIF-1α 
(Pasanen et al., 2010).  Some experts claim that rather than HIF-3 regulating HIF-1 and 
HIF-2, HIF-3 is oxygen dependent and is instead regulated exclusively by HIF-1, not HIF-
2.  Some studies concluded that the second splice variant of the HIF-3 isoform, HIF-
3v2, as well as HIF-3αv4, act as a negative inhibitor in HIF-1α and HIF-2α signaling 
(Maynard, 2005)(Heikkilä et al., 2011)(Heikkilä et al., 2011).  However, one study 
investigated this further, but looked into whether shorter cytoplasmic HIF-3 splice 
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variants elicited different functions than longer nuclear HIF-3 splice variants and found 
varied results (Heikkilä et al., 2011)(Heikkilä et al., 2011). HIF-3 overexpression has also 
been shown to decrease the hypoxia regulated expression of VEGF-A and Enolase2 in 
human vascular cells (Augstein, Poitz, Braun-Dullaeus, Strasser, & Schmeisser, 2011). More 
studies are needed on HIF-3α, but based on the literature, HIF-3α either regulates HIF-1, 
or is regulated by HIFs1 and 2.  Investigating this inconsistency could prove very useful 
to future research.  If HIF-3 in fact regulates HIF-1 and HIF-2 and consequently, their 
target genes like VEGF-A; HIF-3α could be a great target for future studies.  
T a r g e t  G e n e s  D o w n s t r e a m  o f  H I F  
 
As stated, as many as 100 target genes exist for HIF-1 whose activation can lead to 
widespread effects such as angiogenesis, vascular remodeling, erythropoiesis, pH 
regulation, cellular proliferation, apoptosis, vasodilation, migration/invasion, 
catecholamine and iron, and  energy metabolism (Table 1) (Q. Ke & Costa, 2006).  There is 
some redundancy in the target genes of HIF-1 and HIF-2; both HIFs are hypoxia 
inducible and bind to HREs on many of the same target genes (Harris, 2002)(Hu et al., 
2006).  Most important for this study are the processes implicated with metabolic 
remodeling within the GBM microenvironment and are reviewed below (Denko, 2008).  
A n g i o g e n e s i s  
 
Hypoxia mediated HIF expression mediates tumor progression, largely in part due 
to upregulation of genes involved with invasion, metastasis, and new blood vessel growth.  
As described above with the Warburg Effect, tumor cells have a growth advantage in 
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hypoxic, acidic and nutrient deficient areas.  However, tumor cells still have metabolic 
requirements and need ways to transport wastes to prevent cell toxicity and death.  To 
accommodate the need for increased nutrient and waste transport, cancer cells tend to 
have upregulated expression of genes involved with angiogenesis.  Angiogenesis is a 
multistep process involved in creating new vasculature for tissues: this process is hijacked 
in cancer.  Most notably, the endothelial-specific mitogen called vascular endothelial 
growth factor (VEGF), is expressed by cancer cells, which leads to recruitment of 
endothelial cells to hypoxic areas and subsequent endothelial cell proliferation (Mansour et 
al., 2014), which fails to prevent the “chronic hypoxia” characteristic within areas of the 
tumor (Harris, 2002)(Brown & Giaccia, 1998).  Activation of VEGF and other angiogenic 
factors leads to the creation of more vasculature, which slightly decreases the distance that 
oxygen needs to diffuse into tissues while also making nutrient delivery and waste 
transport more possible (Q. Ke & Costa, 2006).  However, the organization and structure of 
the new vessels are weak and hypoxic conditions can remain despite the new vasculature 
(Hida & Klagsbrun, 2005).  It is unclear how well this tumor-induced vasculature 
distributes nutrients to the areas surrounding the tumor.  The new blood vessels are 
unstable; the new vessels close randomly and then sometimes reopen (Brown & Giaccia, 
1998), which provides oxygenated blood to previously hypoxic areas of the tumor in a 
process called ‘reoxygenation injury’ (Prabhakar, 2001).  Free radicals flood the 
surrounding tumor microenvironment and consequently, these areas are resistant to 
radiation treatment because radiation targets cells using oxygen free radicals; hypoxic cells 
are therefore acclimated to this process already (Wouters & Brown, 1997), which provides 
one explanation for the ineffectiveness of radiation as a treatment for some patients.  
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Regardless, hypoxia has been implicated with this vascularization process and HIFs 
are present in various tissues and in various areas of the tumor microenvironment.  Both 
HIF-1 and HIF-2 are highly inducible in hypoxic areas, with varying expressions based 
on specific oxygen levels of the tumor microenvironment and have also been shown to 
upregulate VEGF expression (Holmquist-Mengelbier et al., 2006)(Fukumura et al., 
2001)(Forsythe et al., 1996).  Additionally, cancer stem cells have been found to grow in 
niches near endothelium (Hira et al., 2015), which seems to correlate to HIF-2 expression 
since its expression has been implicated with highly vascularized areas, which typically are 
comprised in part of endothelium.  Overall, angiogenesis is implicated with poor patient 
prognosis in GBM, neuroblastoma, and several other cancers (Holmquist-Mengelbier et al., 
2006)(Pasanen et al., 2010).   
M e t a b o l i c  R e m o d e l i n g  
 
In low oxygen conditions, HIFs are upregulated and cause downstream changes, 
most notably in glucose metabolism.  Although less efficient in some ways, cancer cells shift 
their metabolism from mitochondrial oxidative phosphorylation to the oxygen-
independent process glycolysis but do so aerobically (Figure 4).  Since glycolysis only 
generates 2 ATP molecules from each glucose molecule (Brahimi-Horn, Chiche, & 
Pouysségur, 2007)(Brahimi-Horn, Chiche, & Pouysségur, 2007), more glucose molecules are 
required to maintain cancer cell viability and subsequent aberrant growth (Q. Ke & Costa, 
2006).  This increased glucose uptake into the cell is achieved by up-regulating glucose 
transporters, GLUT1 (SLC2A1) and GLUT3 (SLC2A3) (Denko, 2008) (Q. Ke & Costa, 2006).  
Since the glucose transporters move glucose according to its concentration gradient, a 
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simple upregulation of GLUTs facilitates the increased need for intracellular glucose 
(Denko, 2008) (Ozbudak, Karaveli, Simsek, Erdogan, & Pestereli, 2008).  
There are numerous uses for the intracellular glucose and most of them have been 
directly implicated with HIF-1 (Table 1).  The hexokinase (HK) enzymes are responsible for 
phosphorylating glucose into Glucose-6-phosphate, which is a charged molecule.  The 
phosphorylated glucose can no longer escape the cell through the plasma membrane and is 
instead utilized in several pathways, including glycoprotein synthesis, metabolized via the 
pentose shunt to become ribose, or for glycogen synthesis (Denko, 2008).  However, 
glucose is mostly utilized by glycolysis by further breakdown and involves the following 12 
HIF-inducible glycolytic enzymes: phosphoglucose isomerase (PGI), phosphofructokinase 1 
(PFK1), Aldolase, Triosephosphate isomerase (TPI), glyceraldehyde-3 phosphate 
dehydrogenase (GAPDH), Phosphoglycerate Kinase (PGK), Phosphoglycerate mutase 
(PGM), Enolase, Pyruvate Kinase (PK), and 6-phospho-2-kinase/fructose 2,6 
bisphosphatase (PFKFB1-4) (Table 1) (Denko, 2008).   
In glycolysis, intracellular glucose is broken down to pyruvate by several enzymes, 
including pyruvate dehydrogenase (PDH) (Dengler, Galbraith, & Espinosa, 2014).  
However, pyruvate is not utilized by the mitochondria of hypoxic cells and is mostly 
converted into lactate by the enzyme lactate dehydrogenase (LDHA) through fermentation.  
Excess lactate is one of the two known mechanisms that decreases the intracellular pH and 
consequently needs to be shuttled out of the cell to prevent cell toxicity (Harris, 2002).  
This is accomplished by releasing lactate into the extracellular space via HIF-inducible 
monocarboxylate transporters (MCTs) embedded in the plasma membrane (Table  1) 
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(Chiche et al., 2010).  MCTs have been implicated in many studies and in-vitro knockdown 
has led to in-vitro decreased tumor cell aggressiveness with expected decrease in lactate 
shuttling, cell proliferation, invasion, and metastasis; there was also a distinct decrease in 
in-vivo tumor formation (Morais-Santos et al., 2015).  Carbonic anhydrase (CAIX) 
transporters are also important in contributing to the low pH microenvironment by 
converting carbon dioxide and water to carbonic acid.  In tumors cells with defective LDH, 
there is still a low extracellular pH which implies that CAIXs are a factor for the tumor’s low 
pH (Yamagata, Hasuda, Stamato, & Tannock, 1998).  Transcription of carbonic anhydrase-9 
was initiated by hypoxia in several tumor lines (Wykoff et al., 2000) and is suppressed in 
normoxic conditions (Loncaster et al., 2001), which implies at least an indirect relationship 
with HIFs, with general hypoxia, or with the pH decreases that accompany glycolytic 
changes induced by hypoxia.  Overall, carbonic anhydrases are expressed in many tumor 
types and high expression correlates to poor patient prognosis (Harris, 2002)(Chia et al., 
2001). 
The Warburg Effect asserts that hypoxia and subsequent HIF-1 activation are 
correlated with lactate and pyruvate accumulation, but it has also been found that lactate 
and pyruvate accumulation might also lead to HIF-1 accumulation in both normoxic and 
hypoxic conditions (Q. Ke & Costa, 2006)(Denko, 2008)(Marin-Hernandez, Gallardo-Perez, 
Ralph, Rodriguez-Enriquez, & Moreno-Sanchez, 2009).  As discussed, glycolytic energy 
metabolism might be advantageous to tumor cells due to the fast breakdown of glucose to 
pyruvate followed with the conversion to lactate via fermentation.  Although more ATP per 
glucose is produced from mitochondrial oxidative phosphorylation, it is faster to perform 
aerobic glycolysis for energy and confers advantage over cells that are restricted to aerobic 
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oxidative phosphorylation in the mitochondria, which is also bypassed because of the many 
HIF-1 mediated mechanisms (G. L. Semenza, 2010b)(G. L. Semenza, 2010a)(Papandreou et 
al., 2006).   
In addition to upregulating genes involved with glycolysis, such as glucose 
transporters, (GLUTs), HIF-1 indirectly and directly modulates mitochondrial function in 
hypoxic cells.  HIF-1 indirectly decreases pyruvate flow to the mitochondria by activating 
the master kinase, pyruvate dehydrogenase kinase 1 (PDK1) which has been deemed HIF-
dependent since it requires pyruvate in the Kreb’s cycle to be induced.  However, PDK1 is a 
confirmed direct transcriptional target of HIF-1.  PDK1 is a master kinase that 
phosphorylates the E1 segment of the enzyme phosphate dehydrogenase (PDH), thereby 
inactivating it. This prevents PDH from breaking pyruvate down irreversibly to Acetyl-CoA, 
CO2, and NADH which are used as fuel for the Kreb’s cycle and for the electron transport 
chain (ETC) (Denko, 2008).  Overall, HIF-activated PDK isoforms directly block the flow of 
pyruvate into the mitochondria (R. Thomas, 2001) and prevents oxidative phosphorylation, 
total O2 consumption (Papandreou et al., 2006) by the cell, and reactive oxygen species 
(ROS) generation (Kim, Tchernyshyov, Semenza, & Dang, 2006).  Other HIF-1 inducible 
mechanisms are apparent but were not reviewed in this study.  Targeting aerobic glycolysis 
from multiple approaches might be an effective way to decrease tumor growth.   
G l u c o s e  T r a n s p o r t e r s  ( G L U T s )  
 
GLUT1 and GLUT3 belong to a family of 13 glucose transporters and primarily 
regulate glucose transport due to many factors: such as their wide tissue distribution and 
affinity for glucose (Denko, 2008)(Ozbudak et al., 2008)(Airley & Mobasheri, 2007).  As 
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previously discussed, glucose transporters (GLUTs) 1 and 3 have been involved with 
hypoxia and are a major component of the metabolic remodeling that is characteristic in 
many types of cancer including: endometrial (Ma et al., 2015), gastric (J. Liu et al., 2015), 
squamous cell carcinoma (Asmaa Gaber Abdou, MD, Marwa Mohammad Serag Eldien, MD, 
& Daliah Elsakka, MD, 2015), ovarian cancer (Labak et al., 2016), meningioma (Nes, 
Johannes AP, et al, 2015), and glioblastoma (GBM) (Bache et al., 2015).  As expected,  
GLUT1 mRNA overexpression is induced by H-ras oncogenic transformation and by 
hypoxic conditions (C. Chen, Pore, Behrooz, Ismail-Beigi, & Maity, 2001, p. 9519).  Hypoxia 
induced HIF-1 expression increases GLUT1 and GLUT3 expression levels (Y. Liu et al., 
2009a)(Rooj, Bronisz, & Godlewski, 2016).  
Past research has categorized GLUT-1 and GLUT-3 in various areas of GBM 
microenvironments.  GLUT1 expression levels differ in different areas of the tumor: 
partially a product of hypoxia and of hypoxia-mediated vascularity.  HIF-1 stability is 
regulated by the severity of the local intra-tumoral hypoxia.  Not surprisingly, GLUT1 
expression is correlated with the more hypoxic areas of the tumor microenvironment.  As 
was previously discussed, HIF-1 and HIF-2 correlate with VEGF expression which is the 
primary protein responsible for neovasculature creation.  Sites of angiogenesis have been 
correlated with cancer stem cell niches, as CSCs are commonly found in niches near 
endothelial cells, which are the main cells activated by VEGF expression. Transcription of 
GLUT1 and the stem cell marker Oct4 have been identified in hypoxic areas of GBM and 
when GLUT1 was targeted, self-renewal was inhibited in CSCs.  GLUT3 was shown to 
regulate Oct4 in embryonic stem cells and is likely implicated in cancer stem cell self-
renewal ability (Christensen, Calder, & Houghton, 2015, p. 4).  These studies provide 
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further evidence that GLUT1 and likely GLUT3 are correlated with CSC populations within 
GBM and indirectly with tumor aggression, treatment resistance, tumor recurrence, and 
invasion, to name a few (Labak et al., 2016).  Many of the studies investigating the role of 
GLUT1 in GSCs haven’t determined whether elevated GLUT1 expression can directly confer 
tumor initiating abilities and stem cell self-renewal potential.  Recent studies have found 
that GSCs have increased glycolytic metabolism compared to non-stem cancer cells 
(Hanahan & Weinberg, 2011)(Zhou et al., 2011), which supports the data concluding that 
GLUT1 upregulation is more pronounced in GSC populations.  It is unknown whether 
GLUT1 directly regulates stemness in GSCs, but this is an area for future investigation 
(Shibuya et al., 2015).  Targeting glycolysis as a cancer therapeutic has limitations due to it 
being utilized in many tissues, both healthy and cancerous throughout the body (Hanahan 
& Weinberg, 2011)(DeBerardinis, Lum, Hatzivassiliou, & Thompson, 2008).  The selective 
overexpression of GLUT1 in GSC populations makes GLUT1 a strong contender for future 
targeted treatments (Flavahan et al., 2013).  There are few therapies developed for GLUT3 
expression in CSCs, but its expression in GBM, suggests that it remains a good option for 
future targeted GBM therapies (Flavahan et al., 2013).  
S u m m a r y  
 
The data presented in this study sought to investigate the relationship between 
GLUT1 and HIF-1/ in GBM and fibroblast cell lines.  A time course assay was completed 
to determine if GLUT1 relative mRNA expression levels changed in hypoxic conditions, the 
amount of hypoxia exposure was required to induce these changes, and if the GLUT1 
expression levels correlate to relative mRNA expression of HIF-1/.   This data can be 
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utilized for future studies to identify a direct relationship between HIF-1/ heterodimers 
and GLUT1 in GBM. 
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FIGURE 1: SPATIAL RELATIONSHIP BETWEEN A BLOOD VESSEL, HYPOXIA, AND TUMOR MICRO-
ENVIRONMENT (S. THOMAS ET AL., 2013). 
© 2013 by MDPI (http://www.mdpi.org). Reproduction is permitted for noncommercial 
purposes.  
The figure above depicts the correlation HIF-1 expression and relative oxygen 
concentration in the context of hypoxic tumor microenvironment in tumors and their 
proximity to blood vessels. In normoxia, HIF-1 subunits are rapidly degraded, but the 
mechanisms that degrade them in normoxia are less effective in hypoxic conditions 
resulting in stabilized HIF-1 and subsequent translocation in the nucleus where it binds to 
HIF-1 which together comprise an active HIF-1 heterodimeric protein.  




FIGURE 2: DOMAIN STRUCTURES OF HIF TRANSCRIPTION FACTORS (LISY & PEET, 2008).   
Adapted by permission from Macmillan Publishers Ltd: Cell Death and Differentiation, (HIF 
Transcriptional Activity), Copyright 2008.  
The three HIF paralogs: HIF-1, HIF-2, and HIF-3 and the HIF-3 splice variant called 
inhibitory PAS domain protein (IPAS) which might to negatively regulate HIF-1 mediated 
transcription, but this is controversial.  All the HIF alpha subunits hetero-dimerize with 
HIF-/ARNT subunits, possibly except for the IPAs HIF-3 splice variant, which might only 
bind to a specific HIF-3 subunit.  All the HIFs possess highly similar bHLH and PAS 
domains which mediates the characteristic HIF-/ hetero-dimerization and DNA binding. 
All the HIF- subunits contain oxygen dependent domains (ODDDs) and N-terminal 
transactivation domains (NADs).  The oxygen dependent domains (ODDDs) contain the 
proline sequences that are hydroxylated by PHDs in normoxic conditions, as discussed in 
Figure 6 and Chapter 1. The hydroxylation of these sequences and others targets HIF-1 
for proteasomal degradation which confers HIF- instability in normoxic conditions.  HIFs 
1 and 2 contain oxygen dependent C-terminal transactivation domains (CADs). Both CADs 
and NADs facilitate the recruitment of coactivators and transcription intermediates to the 
HIF- / complex which facilitates association with transcriptional activation of HIF- 
downstream genes.  





FIGURE 3: HIF DIMERIZATION AND DNA BINDING. 
Adapted by permission from Macmillan Publishers Ltd: Cell Death and Differentiation, (HIF 
Transcriptional Activity), Copyright 2008. 
After HIF- stabilization, it translocates to the nucleus and binds to the constitutively active 
HIF-1 subunit, forming a heterodimeric complex.  The heterodimerization of the complex 
is essential to binding to HRE binding. The basic residues near the N-terminus of each 
protein facilitates binding to the nucleotides of the hypoxia response element (HRE) in the 
promoter region of DNA sequences of target genes (Lisy & Peet, 2008).  The heterodimeric 
HIF-/ also recruits cofactors and RNA polymerase II and initiates transcription genes 
that mediate cell metabolism, angiogenesis, erythropoiesis, and many other properties that 









FIGURE 4: THE WARBURG EFFECT (VANDER HEIDEN, 2009) 
Adapted by permission from American Association For The Advancement Of Science: 
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation 
 
The figure above depicts the major differences between normal cellular metabolic 
processes and abnormal cancer metabolism.  When in the presence of oxygen, 
differentiated and non-proliferating tissues metabolize a portion of their glucose into 
pyruvate anaerobically in the cytoplasm by glycolysis, which produces 2 ATP. Then in 
environments with oxygen present, oxidative phosphorylation completely oxidizes most of 
the pyruvate made in glycolysis in the mitochondria. Oxygen is required for oxidative 
phosphorylation to occur, as oxygen is the final electron acceptor for oxidizing glucose. 
When oxygen is reduced, the pyruvate generated by glycolysis can be used to generate 
lactate by anaerobic fermentation as opposed to mitochondrial oxidative phosphorylation, 
which is only done aerobically. Generation of lactate cycles NADH into NAD+ and 
propagates glycolysis repeatedly. Warburg found that cancer cells and normal proliferating 
cells convert most of their glucose to lactate despite whether oxygen was present, aerobic 
glycolysis.  Despite the mitochondria being used less for oxidative phosphorylation, it is 
fully functional at producing ATP.  
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FIGURE 5: MECHANISMS OF HYPOXIA-INDUCIBLE FACTOR 1(HIF-1) STABILIZATION 
Adapted by permission from Macmillan Publishers Ltd: Nature Reviews, Cancer (Hypoxia, 
HIF1 and glucose metabolism in the solid tumour), Copyright 2008.  
HIF-1 is unstable in well-oxygenated tissues due to many mechanisms that degrade it 
within five to ten minutes of its translation (Chiche et al., 2013, p. 112) (Qingdong Ke & 
Costa, 2006, p. 1470) (Cunningham et al., 2012, p. 411)(Q. Ke & Costa, 2006).  However, 
HIF-1 stabilization can be a product of a hypoxic environment or oncogene activation 
associated activation of genes such as Ras, RAF, MAPK, phosphoinosotide-3 kinase (PI3K), 
PTEN, or Akt pathways.  In Figure 6a, the HIF-1 domain structure is shown.  In normoxia, 
the proline (P) sequences 402 and 546 and the asparagine (N) 803 sequences are 
hydroxylated thereby targeting the HIF-1 protein for degradation. In Figure 6b, the 
classical pathway of HIF-1 stabilization is depicted.  In normoxia, the very conserved 
bHLH and PAS domains of HIF-1 have proline sequences (P) that are hydroxylated by the 
enzyme prolyl hydroxylase (PHD); the asparagine sequences (N) are hydroxylated by 
enzymes called factor inhibiting HIF (FIHs).  HIF-1 hydroxylation of the various proline, 
asparagine, and lysine (discussed in Chapter 1) serves as a recognition signal for 
ubiquitination (Denko, 2008)(Stiehl et al., 2006).  The hydroxylated proline sequences are 
recognized by the ubiquitin ligase pVHL that is complexed to elongins B and C, which 
makes the VHL-elongin complex shown above (Jeong et al., 2002) (Stickle et al., 2004).  The 
VHL complex binds to the hydroxylated proline sequences and ubiquitinates it and thus 
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targets it for proteasomal degradation (Qingdong Ke & Costa, 2006, p. 1470)(Stickle et al., 
2004).  However, in hypoxic conditions,  the PHD and FIH enzymes do not function as 
effectively and HIF-1 protein remains stable because it is no longer targeted for 
degradation (Denko, 2008). Additionally, Kreb’s cycle intermediates such as succinate or 
fumarate or mitochondrial reactive oxygen species (ROS) can also inhibit the function of 
PHDs which would also lead to increased HIF-1 stabilization and subsequent hetero-
dimerization with the constitutively active HIF-1 subunit. This heterodimeric complex 
then translocates to the nucleus of the cell before binding to the hypoxia response element 
(HRE) in the promoter region of target DNA sequences. 
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TABLE 1: HIF-1 TARGETS THAT REGULATE GLUCOSE METABOLISM (DENKO, 2008). 
Adapted by permission from Macmillan Publishers Ltd: Nature Reviews, Cancer (Hypoxia, 
HIF1 and glucose metabolism in the solid tumour), copyright 2008.  
Expression of hypoxia inducible factors (HIFs) has been shown to mediate much of the 
characteristic metabolic remodeling that occurs in cancer cells. Specifically, glucose entry is 
upregulated by upregulating expression of GLUT1 and GLUT3 transporters. Additionally, 
glycolytic enzymes are upregulated to promote glycolysis and fermentation as opposed to 
the normal aerobic oxidative phosphorylation that occurs after brief glycolysis. Also, 
monocarboxylate transporters are upregulated to shuttle out the excess lactate that gets 
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Many studies have discussed the roles of HIF-1 and GLUT1 in cancer metabolism. 
However, it is unknown whether there is a direct relationship between them in a 
Glioblastoma (GBM) in-vitro model. In other systems, the heterodimeric HIF-1/ complex 
binds directly to the Hypoxia Response Element (HRE) on the GLUT1 promoter to drive 
expression of GLUT1 (Amann et al., 2009). In this study, changes in HIF-1 and GLUT1 
relative mRNA expression were measured in response to changes in relative oxygen 
concentrations utilizing reverse transcription followed by End-Point Polymerase Chain 
Reaction (EP-PCR) and Quantitative Polymerase Chain Reaction (qPCR) in a GBM in-vitro 
model.  EP-PCR was conducted to test whether the genes of interest were expressed at all. 
Then qPCR was conducted to quantify the amount of mRNA transcripts that were 
transcribed over time in a hypoxic environment.  
Hypothesis 1: GLUT1 and HIF-1 expression in GBM cell lines is directly correlated with in-
vitro hypoxic conditions.  
Overall Research Questions: 
• Does the expression of HIF-1 and GLUT1 transcripts change in hypoxic conditions? 
How long are hypoxic conditions required to induce these changes?  
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• Does HIF-1 gene expression directly correlate with GLUT1 and relative oxygen 
concentrations?  
Aim 1: Determine the presence or absence of HIF-1, HIF-1, and GLUT1 in U87MG GBM 
cells and in MSU1.1 cells in both in-vitro normoxic and hypoxic environments using EP-PCR 
and gel electrophoresis.  
• Aim 1a: Generate and test the designed PCR primers and confirm the presence or 
absence in expression of HIF-1, HIF-1, and GLUT1 in both U87MG GBM cells and 
MSU1.1 cells.  
• Aim 1b: Characterize the presence or absence of expression of HIF-1, HIF-1, and 
GLUT1 in both normoxic (20% O2) and hypoxic (5% O2) environments using EP-PCR 
and gel electrophoresis.  
Aim 2: Quantify the relative expression levels of HIF-1, HIF-1, and GLUT1 in GBM using 
qPCR.  
• Aim 2a: Quantify relative gene expression levels of HIF-1, HIF-1, and GLUT1 in 
both U87MG glioblastoma cells and MSU1.1 fibroblast cells while grown in-vitro in a 
normoxic control (20% O2) environment.   
• Aim 2b: Quantify relative gene expression levels of HIF-1, HIF-1, and GLUT1 in 
both U87MG glioblastoma cells and MSU1.1 fibroblast cells while grown in-vitro in a 
hypoxic environment (5% O2).   
Aim 3: Determine whether there is a positive correlation between relative expression of 
HIF-1, HIF-1, and GLUT1 in U87MG and MSU1.1 cells and whether it correlates with in-
vitro hypoxic conditions over time (0, 3, 6, 12, or 24 hours).   
 









P C R  P r i m e r  D e s i g n  
 
 
Splice variants of the genes of interest were evaluated using the UCSC Genome 
Database. The NCBI Gene Bank provided further information about splice variants and the 
mRNA sequences. The NCBI primer design tool was used to pick primers that amplified the 
exon-exon junctions, to amplify mRNA sequences of the genes of interest.  Primers were 
picked based on their predicted PCR amplicon size. The primers with predicted amplicons 
between 80-400 bp were chosen, as they would be more successful in both End-Point and 
qPCR. The IDT Oligo Analyzer tool (www.idtdna.com) was used to ascertain the likelihood 
of the primers forming primer dimers and other secondary structures, as they impede 




C e l l  C u l t u r e  
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Human Glioblastoma cell lines U87MGMG and LN229 cells as well as the human 
foreskin fibroblast line MSU1.1 were utilized in this study. Both U87MG and LN229 cell 
lines are commonly used as in-vitro models for glioblastoma research studies. MSU1.1 is a 
fibroblast cell lines and was used as a control cell line due to their non-cancerous 
phenotype. Although the efficacy of using MSU1.1 cells as a control is a limiting factor in the 
study, it was deemed the most appropriate option available to us. The use of MSU1.1 cells 
in this study was also highly controlled; passage numbers were kept as low as possible and 
cells were not grown past 65% confluency to minimize the chance of changes to the cell 
that acquire different characteristics like a cancer cell or cancer cell line.  
All cell lines were removed from cryostasis in liquid nitrogen and revived back into 
culture. Cell cultures were expanded in T-75 flasks and then frozen back in 1.5 mL aliquots 
of freeze media at a ratio of 10% DMSO and 90% Media. Frozen aliquots were placed in 
cryostasis for the ease of culturing cells as needed for experimental assays. This method 
helped to control for gene expression changes that would potentially occur because of 
differing cell passage numbers.  
All cultured cell lines were expanded in standard cell conditions of 37C, 5% CO2, 
20% O2 at 100% humidity. U87MG and MSU1.1 cells were cultured in EMEM + 10% Fetal 
bovine serum (FBS) (Atlanta Biological, Atlanta, GA).  LN229 cells were cultured using MEM 
+ 10% FBS. U87MG and LN229 cultures were expanded in T-75 cell culture flasks until they 
were 70-80% confluent. LN229 cells were discontinued from the project due to time and 
budget constraints. MSU1.1 cultures were only grown to approximately 60% confluency to 
minimize any chance of phenotypic changes induced by over-growth. For the hypoxia time 
course assay, cells were plated and were grown in a normoxic (20% O2) environment 
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overnight (12-15 hours), were washed with 1X PBS (Lonza, Cat# 17-516F/12), to remove 
any cellular wastes that had accrued overnight followed by the application of fresh cell 




H y p o x i a  T i m e  C o u r s e  A s s a y :  C e l l  C u l t u r e  D e s i g n  
 
 
In this experiment, hypoxic conditions of 5% oxygen were used as the treatment 
prior to gene expression analysis.  In preparation for each assay, cells were revived from 
cryostasis, split once in a 1:4 ratio and were then plated for the assay immediately after the 
last cell culture split. Cells were split in this manner and were not counted due to time 
constraints.  Experimental cells were plated in 10 cm treated cell culture plates at 30-50% 
confluency and the and the cells adhered to the plate overnight (approximately 12-15 
hours) in the presence of 20% O2 chamber.  
The following morning, the experimental cell plates were removed from the 
incubator. The cell culture media was aspirated, and cells were washed with 2-3 mL of 
sterile 1% PBS.  The cells were then fed 10 mL of fresh media, respective to each cell line. 
The experimental cell cultures were then transferred to the hypoxic (5% O2) chamber for 
specified times of 3 hours, 6 hours, 12 hours, and 24 hours. The control cells were only 
grown in normoxic conditions, were either lysed after spending 0 hours in hypoxia or after 
24 hours of growth in hypoxia.  In the data analysis below, the control cells are referred to 
as 0 hours spent in a hypoxic chamber.  At each time point, the cell culture dishes were 
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removed individually from the hypoxic chamber and were lysed directly in their cell 
culture plates using the RLT lysis buffer from the Qiagen RNeasy kit (Cat# 74104).  This 
was repeated for each of the three biological replicates for each hypoxia exposure time 
point in the assay.  Overall, the experiment was done once, but included three biological 





H y p o x i a  T i m e  C o u r s e  A s s a y :  D i r e c t  C e l l  L y s i s  
 
 
Direct cell lysis in 10 cm cell culture plates, as opposed to T-75 flasks, to allow for 
quicker cell lysis. The direct cell lysis was done to reduce any potentially reversible 
changes in the hypoxia induced gene expression from occurring.  In total, three control 
(normoxia exposed) plates were lysed and three cell experimental culture plates grown in 
hypoxia were lysed after each time point in the assay: 3 hours, 6 hours, 12 hours, or 24 
hours.  This design was repeated for each cell line: MSU1.1 (control), LN229 (glioblastoma), 
and U87MG (glioblastoma).  However, LN229 was quickly removed from the project due to 





R N A  I s o l a t i o n  a n d  F i r s t  S t r a n d  c D N A  S y n t h e s i s  
 
RNA was isolated and homogenized using a QiaShredder (Qiagen, Cat # 79654). 
RNA was isolated from cell lysates using a RNeasy mini kit (Qiagen). The full RNA isolation 
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procedure is included in Appendix C. The isolated RNA was quantified using a 
ThermoScientific Nanodrop 2000c. The RNA was then converted into single strand cDNA 
using either Promega AMV Reverse Transcriptase (Promega, Cat # M5108) or 
ThermoFisher Maxima Reverse Transcriptase (Cat # EP0741) and incubated in a Bio-Rad 
T100 Thermal Cycler. Further details on cDNA synthesis are included in Appendix A. All the 
qPCR data collected was with cDNA synthesized using the ThermoFisher reverse 
transcriptase and the Promega RT was utilized only in the End-Point PCR.  
Relative mRNA expression levels were analyzed in place of the proteins in question. 
This method confirmed that the mRNA coding for the hypoxia inducible factor family of 
transcription factors was being transcribed.  The presence or absence of mRNA of the alpha 
and beta subunits of HIFs 1-3 were evaluated with End Point PCR (EP-PCR).  HIF-1α and 
HIF-1 were evaluated further using Quantitative Real Time PCR (qPCR) to note the 
relative expression levels.  Since the transcription and translation of glucose transporters, 
specifically GLUT1, is elevated in certain cancers, the transcription of GLUT1 was also 





E n d - P o i n t  P o l y m e r a s e  C h a i n  R e a c t i o n  
 
 
End-Point PCR (EP-PCR) was conducted to determine whether the designed PCR 
primers were functional and then to determine presence or absence of HIF-1α, HIF-1, and 
GLUT1 mRNA transcripts in both normoxic and hypoxic environments. Additional genes of 
interest were evaluated in the End-Point PCR study: HIF-2α, HIF-2, HIF-3α, HIF-3, and 
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GLUT3. End-Point PCR was conducted on samples from U87MG-MG, LN229, and MSU1.1 
cells.  
The reaction was performed using a Bio-Rad T100 Thermal Cycler. The program 
initiated at 95C for 3 minutes. Then the reaction performed 35 cycles of: 95C for 30 
seconds for denaturing, decreased to 55C for 30 seconds for primer annealing, and was 
raised to 72C for 1 minute for DNA elongation. After the 35 cycles, the reaction was 
terminated with an incubation at 72C for 5 minutes before incubating at 12C. The PCR 
product was either subjected to gel electrophoresis or was stored at -20C freezer.  
To determine the presence of DNA products produced from the End-Point PCR 
reaction, the products were electrophoresed in a 1.0% agarose gel in Tris/Borate/EDTA 
(TBE) buffer. When the mixture was cool to the touch, 1 L of 10 g/L ethidium bromide 
was added to the solution and then was mixed. The mixture was further cooled in the fume 
hood and was then poured into a standard gel box setup. A total of 5 L of Blue/Orange 6X 
Dye (Promega, Cat# G1881) was added to each 25 uL PCR product, yielding a total 30 L 
total volume per lane. A 1kb and/or a 50 bp ladder were included on each gel. The gel 
electrophoresis was conducted using the following parameters; ~120 V, for 60-75 minutes 
in a running buffer solution comprised of 0.5x TBE buffer. Gels were imaged using a NMU 





R e a l  T i m e  ( Q u a n t i t a t i v e )  P o l y m e r a s e  C h a i n  R e a c t i o n  
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Real time PCR (qPCR) was conducted to determine the amount of time that was 
needed to induce relative expression changes to occur in HIF-1α, HIF-1 and GLUT1 mRNA 
expression levels after exposure to hypoxic conditions (5% O2).  
The real-time PCR (qPCR) reaction was performed with the GoTaq qPCR Master Mix 
(Promega, Cat# A6001). The master mix consisted of a propriety SYBR green dsDNA 
intercalating dye, primers, dH2O, and a low level of carboxy-X-rhodamine (CXR) reference 
dye. The reaction size recommended by the manufacturer was 50L, but the reaction size 
was scaled down to 20L to minimize project cost. The small volume necessitated extra 
care to be taken in pipetting evenly throughout all the individual PCR reactions. The 20 L 
reaction had the following components:  
 10 L Master Mix 
 0.2  L CXR reference dye 
 0.8  L Forward Primer 
 0.8  L Reverse Primer 
7.4  L Nuclease-free water 
 
Total:  19.2  L Master Mix 
 
A total of 19.2uL of master mix without primers was added to each of the three 
negative control wells in the 48 well sample PCR plate. 0.8uL of PCR grade nucleotide free 
water (Promega, Cat#A6001) was added to each of the control wells. 0.8 L of cDNA was 
added to the experimental plates.  20uL total volume was added to each well in the 48 
sample PCR plate. The reaction was performed using an Applied Biosciences StepOnePlus 
thermocycler and was programmed for 1 cycle at 95C for 10 minutes and then 40 cycles of 
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15 seconds at 95C to denature the cDNA, followed by a decrease in temperature to 55C 
for 1 minute for annealing, and then increased for elongation to 73C for 30 seconds.  
In qPCR, fluorescent signal is accumulated and denotes a positive signal in the PCR 
reaction. The number of cycles needed for the accumulated fluorescence to pass a 
threshold value is referred to as the cycling threshold (CT) value.  CT values are inversely 
proportional to the amount of nucleic acid. Therefore, housekeeping genes or highly 
expressed genes will have a low CT value.  The comparative Ct method was used to analyze 
the data which was exported to Excel. The comparative Ct method was used to analyze 
gene expression levels, as it seemed appropriate due to having a large sample size: 
differently treated samples, two cell lines, and three genes of interest (Wong & Medrano, 
2005). This method involves normalizing the gene of interest to a house keeping gene: 
GAPDH in this case to calculate a delta Ct (dCt) (Brugè, Venditti, Tiano, Littarru, & Damiani, 
2011)(Brugè, Venditti, Tiano, Littarru, & Damiani, 2011). The delta Ct values of the hypoxia 
treated cells were compared to the delta Ct values of the normoxia exposed (control) cells 
to get a delta delta Ct (ddCT) value (Livak & Schmittgen, 2001). Relative gene fold change 
was calculated by 2^-(delta delta Ct). Relative fold change shows whether there is any 
change in relative gene expression. A fold change above a value of one denotes a gene up-
regulation; a negative value for relative gene fold change indicates that the gene was down-
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S t a t i s t i c a l  A n a l y s i s  
 
 
Many methods were initially used to test the significance of the qPCR data including 
factorial analysis using SPSS software and GraphPad-PRISM software for two-way ANOVA 
with repeated measures and student t-tests. Two-way ANOVA was utilized to create graphs 
depicting mRNA expression fold change of GLUT1, HIF-1 α, and HIF-1 in U87MG cells and 
MSU1.1 cells at each of the time points in the hypoxia time course assay (Figures 11-13).  
However, more in-depth analysis was needed to determine which variables had 
correlative relationships.  The large number of dependent variables in the study: three 
genes of interest, two cell lines, and five treatment time points, using a factorial cell culture 
setup, necessitated the use of a multivariate analysis of variance, MANOVA (Stevens, 
2009)(Warne, 2014).   The data was log transformed and then was analyzed with MANOVA 
using SPSS software. One outlier was present in the data and was removed from the data 
set. However, the removal of the outlier did not significantly change the results of the 
MANOVA analysis. MANOVA is an extension from the univariate analysis of variance 
(ANOVA).  An ANOVA can evaluate the statistical differences among a single dependent 
variable. For example, an ANOVA could determine whether there were changes in the 
relative expression of GLUT1 as a product of the time spent in a hypoxic environment. The 
MANOVA can evaluate the effects of several dependent variables and compiling them to 
create a single continuous variable.   This study analyzed the effects of cell line (U87MG and 
MSU1.1) as well as the combined effects of both hypoxia treatment and cell line. The 
independent variable in the study was the time that cells spent in either normoxic (control) 
or hypoxic (experimental) environments prior to being lysed for subsequent RNA isolation. 
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The many multiple dependent variables in the study necessitated the use of a MANOVA to 
understand whether any statistical significance was due to variance within any of the 
dependent variables or whether it was due to the time spent in a hypoxic environment 
(independent variable). Pairwise comparison analyses were conducted to find correlations 
between the expression levels of the genes of interest in the cell lines that were tested 
while also testing whether different amounts of time in a hypoxic environment also had an 





L i m i t a t i o n s  o f  S t u d y  
 
 
Limitations were present in the usage of MSU 1.1 cells as a control line, as they are a 
cell line made by transfecting diploid fibroblasts with the viral v-Myc gene (Hurlin, Maher, 
& McCormick, 1989) . Making a cell line inherently gives the cells, cancerous or not, 
different genetic and phenotypic profiles that limit the replicability of the study as well as 
the applicability when applying this study to in-vivo GBM studies. However, the growth of 
MSU1.1 cells was carefully controlled in this study: cells were not grown past their 
recommended confluency and were examined carefully for any phenotypic changes prior 
to hypoxic exposure and subsequent lysis.  Since normal human control cells were not 
readily available, the MSU 1.1 fibroblast cell line was used.  Although the sample size for 
PCR was relatively small, there were sufficient replicates done for the data sets to pass the 
needed statistical tests for variance and normality. Likely due to human error there was 
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some variability in the delta CT values. However, this variability was accounted for in the 
statistical analysis and proved to be insignificant.   
 
TABLE 2: PCR PRIMER SEQUENCES 
The following sequences were designed for this study and were utilized in EP-PCR and 
qPCR studies. As discussed on page 29, PCR primers were designed to have predicted 
amplicon sizes between 80-400 base pairs, to increase qPCR success, as small amplicons 
sizes are required to have successful qPCR.  All primers were utilized in EP-PCR and qPCR 
studies and tested for expression of the following target genes in U87MG and MSU1.1 cells: 
HIF-1α, HIF-1 sets 1 and 2, HIF-2α, HIF-2, HIF-3α, HIF-3, GLUT1, and GLUT3.  
Primer Forward	Primer	Sequences	(5'-3') Reverse	Primer	Sequences	(5'-3') Use	of	Primer
HIF-1α	 ACCTATGACCTGCTTGGTGC GGCTGTGTCGACTGAGGAAA End	Point	and	qPCR
HIF-1b Set	1 CCCCACCCAAGGAGCAA	 AGAAAAGCCTGAGCGGGTAGT	 End	Point	and	qPCR
HIF-1b Set	2 CTTTTCTGCCCAGGTGGCTA ATGGAGTCTGAAAGCTGCCC End	Point	PCR
HIF-2α TACAATCCTCGGCAGTGTCC GAGGCTGTCAGACCCGAAAA End	Point	PCR
HIF-2b CGGCAGCTAAACCAGAGTCA ACTTTCAGCGAACCCTGGAG End	Point	PCR
HIF-3α	Set	1 ATAAGTCAGGGAGGGGACAGAG TAGCAGGCATCCAGTGGTTC End	Point	PCR
HIF-3α	Set	2 CACTGAGGCAGTGGAGACAG GGCTCATTCAGGTTCAGGAGT End	Point	PCR
HIF-3α	Set	3 GACACTGAGGCAGTGGAGAC CATTCAGGTTCAGGAGTGGGG End	Point	PCR
HIF-3b AGAAGGTGGCCCAAAGAGGA GGAGGCGTACTCGTGATGTT End	Point	PCR
GLUT1 GTGACAAGACACCCGAGGAG CCTGGAGCCGTTAAGTCCTG End	Point	and	qPCR
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In previous work, the heterodimeric HIF-1 complex activity was shown to positively 
correlate with a hypoxic tumor microenvironment (G. L. Semenza, 2002). After hypoxia 
induced stabilization of HIF-1, the HIF transcription factor translocated to the nucleus and 
bound to the hypoxia response element on target DNA: one such target is GLUT1 (G. L. 
Semenza, 2010b).  This study sought to establish the relative mRNA expression levels of 
HIF-1α, HIF-1, and GLUT1 in U87MG GBM and MSU1.1 fibroblast cells in hypoxic and 
normoxic conditions. Additionally, this study sought to determine whether there is a direct 
correlation between HIF-1 and GLUT1. As a first step, we investigated whether HIF-1α/ 
heterodimeric complexes were being transcribed into mRNA.  This study served as a 
precursor step to future studies investigating the HIF-1 complex at the protein level and its 
interaction with GLUT1.   
PCR primers for HIF-1α, HIF-1, HIF-2α, HIF-2, HIF-3α, HIF-3, GLUT1, and GLUT3 
were designed (Table 2) and tested using End-Point PCR and subsequent gel 
electrophoresis for U87MG cells. HIF-1α and two sets of HIF-1 products from U87MG cell 
lysates were detected in both normoxic and hypoxic conditions with the correct band 
length for their expected PCR product sizes: 98 bp (HIF-1α), 55 bp (HIF-1-Primer Set 1), 
and 80 bp (HIF-1-Primer Set 2) (Figure 6).  Similarly, in Figure 7, the PCR products for 
HIF-2α (183 bp) and HIF-2 (234 bp) are shown at the correct product size. HIF-3α 
amplification was not conclusively established in U87MG cells in this study.  There were 
multiple bands in lanes 8 and 9 rather than having a single band of 70 bp using one of two 
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primer sets designed for HIF-3α (Figure 7).  The second primer set designed for HIF-3α 
should have had a product of 72 bp in lanes 2 and 3 of the gel shown in Figure 8.  Both 
attempts to detect a PCR product for HIF-3α using either primer set were unsuccessful. 
However, there was successful amplification of HIF-3 (177 bp) and GLUT1 (231 bp) in 
U87MG cells (Figure 8).  GLUT3 expression was also found in U87MG PCR reactions from 
both U87MG cells in a normoxic and hypoxic environment (Figure 9).  In Figure 10, the 
presence of HIF-1α, HIF-2α, HIF-2, HIF-3α, HIF-3, and GLUT1 were tested in MSU1.1 cells 
(Figure 10) and the presence of all but HIF-3α were confirmed.  
Overall, the expression of genes HIF-1α, HIF-2α, HIF-2, HIF-3, GLUT1, and GLUT3 
were observed in U87MG cells in normoxic and hypoxic conditions.  GLUT3 expression was 
not tested in MSU1.1 cells using EP-PCR.  Most of the primers were tested in MSU1.1 cells 
grown in hypoxia for 48 hours, except for HIF-1, due to issues designing an effective PCR 
primer (Figure 10).  However, HIF-1 expression was measured using qPCR.  Agarose gels 
were also run using normoxic control cDNA from MSU1.1 cells (data not shown).   
There were also recurrent issues with designing a HIF-3α primer.  Preliminary EP-
PCR experiments could not confirm HIF-3α expression in either U87MG cells or in MSU1.1 
cells.  Inappropriately sized bands were present in all EP-PCR amplification agarose gels 
conducted with U87MG cell mRNA (Figures 7 and 8) and in MSU1.1 cell mRNA samples 
(Figure 10).  Consequently, the study of HIF-3 was discontinued and subsequent qPCR 
experiments were not performed.  New PCR primers were needed to continue the study of 
HIF-3 but a new set of primers was not designed due to time and budget constraints.  
The End-Point PCR was followed up with qPCR to measure the relative mRNA 
expression levels of HIF-1α, HIF-1, and GLUT1 in U87MG and MSU1.1 after hypoxia 
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exposure for 0, 3, 6, 12, or 24 hours.  The resulting CT values for each gene for each run of 
qPCR that was conducted. These values were compiled and the technical replicate values 
for each biological replicate were averaged (data not shown).  As discussed previously, the 
comparative CT method was utilized to analyze the results of each qPCR. This method is 
described below using GLUT1 as the example gene of interest.  
Equation 1: Calculate the of hypoxia treated relative genes (Experimental Treatment) 
 
Equation 2: Calculate the of normoxia treated qPCR runs (Control treatment) 
 
Equation 3: Calculate the difference between ∆CT Hypoxia (Experimental Treatment) and 
∆CT Normoxia (Control Treatment). 
 
 Using Equation 1, the delta CT values were calculated for each gene of interest after 
exposure to hypoxia at the various time points in the hypoxia time point assay.  These delta 
CT values were referred to as ‘∆CT (hypoxia treated)’. Then in Equation 2, the delta CT 
values of the normoxia exposed gene of interest, GLUT1, were measured and then 
normalized to the CT of the normoxia exposed housekeeping gene GAPDH.  In Equation 3, 
the ∆∆CT of GLUT1 was calculated by normalizing the effects of hypoxia to the effects 
shown in normoxia. The ∆CT values for each gene of interest measured at each time point 
in the hypoxia time point assay in both U87MG and MSU1.1 cells are depicted in Table 4.  
The ∆∆CT values were converted into relative fold change by using Equation 4 below. 
Equation 4:   
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The relative fold change data was log transformed and one outlier was removed 
from the data, which did not significantly change the overall results (data not shown).   The 
data was then analyzed for significance using Multivariate Analysis of Variance (MANOVA) 
using SPSS software.  MANOVA was conducted to test whether each of the independent 
variables: cell line, relative oxygen concentration, and time spent in variable relative 
oxygen conditions had effects on the dependent variables: the expression of the genes HIF-
1α, HIF-1, and GLUT1.  In this study, several multivariate test statistics were used: Wilks’ 
Lambda, Pillai’s Trace, Hotelling’s Trace, and Roy’s Largest Root, shown in Table 4.  Of 
interest was the Wilks’ Lambda statistic from the F test, which represents the percentage of 
variance within the dependent variables, which are the genes of interest: HIF-1α, HIF-1, 
and GLUT1. The desired result entails that the p-value denoting significance fall in the 
range of zero to one, ideally as close to zero as is possible.  
The Wilk’s Lambda test indicated that there was a statistically significant effect 
(p=0.000) between the independent variable, cell line, and the expression level of all the 
dependent variables when analyzed together as a group: HIF-1α, HIF-1 , and GLUT1 
(Table 4).  Likewise, the other independent variable, hypoxia treatment, had a statistically 
significant effect (p=0.000) on the expression levels of the entire group of genes of interest: 
HIF-1α, HIF-1 , and GLUT1 (Table 4).  It was hypothesized that both HIF-1α, HIF-1, and 
GLUT1 expression levels would be directly proportional to in-vitro hypoxic conditions.  
Therefore, our null hypothesis was rejected in regard to the expressions of HIF-1α and 
GLUT1 and confirmed for HIF-1 expression.  It was expected that both HIF-1α and HIF-1 
expression would be proportional to relative oxygen concentrations in GBM cells as HIF-1 
expression has been found in several types of cancer (C. Chen et al., 2001, p. 1) (G. L. 
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Semenza, 2007).  Likewise, it was expected that GLUT1 expression would also increase in 
hypoxic conditions, as it is thought to be directly downstream from HIF-1, as well as HIF-2 
and possibly HIF-3 in an indirect manner (Richardson, Knowles, Tyler, Mobasheri, & 
Hoyland, 2008).  GLUT1 upregulation has been identified in several types of cancer (Amann 
et al., 2009, p. 1)(Krzeslak et al., 2012).  
The combined effects of the two independent variables (cell line and hypoxia 
treatment) had significant interactional effects (p=0.004) on the expression of HIF-1α, HIF-
1, and GLUT1 as well (Table 4).  Overall, the multivariate analyses supported our 
hypothesis in the context of all the genes of interest when they are lumped together as one 
dependent variable.  Additionally, the significance values found with the Wilk’s Lambda 
analysis were also seen with the other three multivariate tests mentioned above and are 
shown in Table 4.  However, the multivariate analyses were not capable of determining 
whether the independent variables, cell line and hypoxia exposure, led to expression 
changes in each individual gene.  
This general significance found using the MANOVA overall test necessitated further 
study of the effects that each independent variable had on the entire group of dependent 
variables, the genes of interest (HIF-1α, HIF-1, and GLUT1) (Table 5). To conduct this 
analysis, two-way ANOVAs were utilized and can be visualized in Figures 14-16.  The 
results from these ANOVAs concluded that the independent variable, cell line, had a 
significant univariate effect on the dependent variables of HIF-1α expression (p = .001) and 
GLUT1 expression (p = .000). Cell line had a significant control over the expression of these 
two genes individually. Therefore, the affected expression levels of HIF-1α and GLUT1 
cannot be correlated to one another from the data provided in Table 5.  This ANOVA also 
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identified that the in-vitro hypoxia exposure had a single univariate effect on the expression 
of the following genes: HIF-1 (p = .018), and GLUT1 (p = .000).  When the effects of both 
independent variables (cell line and hypoxic treatment) were combined, there was only a 
significant effect seen in GLUT1 expression (p = .002), shown in Table 5.   Overall, this 
univariate ANOVA was useful in determining the effects that each independent variable had 
on each dependent variable (gene expression levels) individually but could not correlate 
the effects seen in the dependent variables together as was possible in the MANOVA 
depicted in Table 4.   
In this study, a two-way MANOVA (Table 4) and multiple univariate ANOVAs (Table 
5) were utilized to analyze the gene expression data from the qPCR gene expression 
studies. To better understand the data collected, a MANOVA was used. The two-way 
MANOVA revealed that there were statistically significant effects on gene expression levels 
from the following independent variables: cell line, hypoxia exposure treatment, and 
interaction effects from the combined effects of cell line and hypoxia exposure treatment 
(Table 4). Subsequent two-way ANOVAs further analyzed the effect that each individual 
independent variable, cell line or hypoxia exposure, had on each gene expression level 
(HIF-1α, HIF-1, and GLUT1) (Table 5).  Put differently, the above studies analyzed the 
general effect that each independent variable had on the entire group of dependent 
variables with the MANOVA (Table 4) followed by the specific effect that each independent 
variable had on each dependent variable individually using multiple univariate ANOVAs 
(Table 5).   
These studies were followed with analysis using a pairwise comparison model from 
the univariate ANOVAs that followed the MANOVA (Tables 6-8).  These analyses 
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characterized the effects that all of the various time points spent using hypoxia 
environment exposure treatment (0, 3, 6, 12, and 24 hours) had on the expression of each 
gene of interest individually, as opposed to looking at the effects of general hypoxia without 
specifying significance to any hypoxia time point. Overall, the pairwise comparison analysis 
compared the expression levels of each gene after the cell lines spent various amounts of 
time (0, 3, 6, 12, or 24 hours) in a hypoxic environment.  Between the time zero of the assay 
and 3 hours spent in hypoxia, HIF-1α expression showed a statistically significant change, 
but no other significant HIF-1α expression changes were evident between any of the other 
hypoxia time points or to the time zero in the assay (Table 6).  Since HIF-1α expression has 
been deemed acutely hypoxia dependent, it was surprising to see that the only significant 
change in expression occurred in the first 3 hours spent in hypoxia.  Initially, it was 
expected that HIF-1α expression would be upregulated for the first 6 hours of the study.  
However, the literature seems to support that HIF-1α expression peaks transiently in the 
first few hours of hypoxia before being degraded (Holmquist-Mengelbier et al., 2006).  
However, several other studies have found that HIF-1α stabilization and expression 
tends to occur after short periods (acute) of exposure to hypoxia rather than when exposed 
to hypoxia more chronically (12+ hours) (Holmquist-Mengelbier et al., 2006).  This study 
was not designed to determine the amount of time necessary to stabilize HIF-1α, but rather 
to determine that it was expressed and whether its expression and stabilization correlated 
with HIF-1, other HIFs, and GLUT1.  Since HIF-1 expression appears to be more related to 
acute exposure to hypoxia as opposed to chronic exposure (Holmquist-Mengelbier et al., 
2006), it was not surprising that HIF-1 expression was not expressed at significant levels 
between all of the other time points spent in a hypoxic environment in this study (Table 6).  
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As described above, pairwise comparison analyses of HIF-1 expression levels 
between each of the time points in the hypoxia exposure assay.   Between time zero of the 
assay and six hours in hypoxia (p = .005), the expression of HIF-1 changed in a statistically 
significant manner. Other significant HIF-1 expression changes occurred between time 
zero and 12 hours in hypoxia (p = .002) as well as between 12 hours and 24 hours (p = 
.037) in a hypoxic environment (Table 7).  Since HIF-1  is the binding partner for HIF-1α, 
although it is allegedly constitutively expressed, it would be assumed that the expression of 
the two binding partners would coordinate with one another. HIF-1 downstream signaling 
could depend on the amount of HIF-1 present. It was expected that HIF-1 expression 
would be stable this study and that HIF-1α would be variable and it was thought to display 
its hypoxia responsive downstream signaling within the first three hours of HIF-1α being 
stabilized, as HIF-1α has been said to mediate an acute response in hypoxia whereas HIF-
2α supposedly mediates downstream signaling in a more chronic response in a hypoxic 
environment.  Some reports claim that HIF-1 binds to alpha subunits of other HIF 
isoforms, most notably HIF-2α.  
 The pairwise comparison then measured the expression changes of GLUT1 (Table 8 
and Figure 16), which was more widely affected by time spent in a hypoxic environment 
than HIF-1α or HIF-1. Statistically significant changes in GLUT1 expression were evident 
between the following hypoxia time points: 0-3 hours in hypoxia (p = .000), 0-6 hours in 
hypoxia (p = .000), 0-12 hours in hypoxia (p = .001), 0-24 hours in hypoxia (p = .000).  
There have been reports that both HIF-1 and HIF-2 expression modulate glucose 
metabolism and have been shown to upregulate genes involved with metabolism, notably 
GLUT1 and GLUT3.  As reported above in this study, HIF-1α and HIF-2α expression changes 
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occur after differing lengths of time spent in a hypoxic environment, which could mean that 
GLUT1 expression is being constantly upregulated due regardless of which HIF is 
upregulated at the time, since both HIFs 1 and 2 have been implicated with GLUT-1 
upregulation.  
Next, pairwise comparisons were conducted to analyze the effects of cell line on the 
expression of each gene. Shown in Table 9, HIF-1α expression was significantly different in 
U87MG versus MSU1.1 cells, which was expected, but the MSU1.1 line has not been well 
characterized to this point making this finding potentially novel.  Most notably is that HIF-
1α expression can be upregulated by oncogenic signaling, which is typical in cancerous 
cells but not in healthy cells, which in this study are represented by the MSU1.1 cell line.  
Additionally, aberrant signaling can mimic hypoxic conditions by initiating the expression 
of HIF downstream genes, but while bypassing HIF.  This is likely true with the expression 
of vascular endothelial growth factor, VEGF.  Aberrant signaling of many genes can initiate 
hypoxic conditions and the subsequent expression of HIF-1α, which can account for why 
there are significantly different expression levels based on the cell line they are expressed 
in (U87MG cancer cells versus MSU1.1 fibroblast cells).   The HIF-1 expression changes 
were not significantly resulting from the cell line it was expressed in.  Not surprisingly, the 
expression of GLUT1 was significantly tied to the cell line.  It is well documented that 
GLUT1 expression is typical in normal tissue and is overexpressed in cancerous tissues.  
Knowing this, it is not surprising that GLUT1 expression is significantly elevated in the 
cancer cell line U87MG as opposed to the ‘normal’ MSU1.1 cells used in this study.  
However, after conducting EP-PCR, this study only encompassed two cell lines (MSU1.1 
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fibroblasts and U87MG cancer cells) for the qPCR aspects.  Therefore, subsequent studies 
are needed to confirm and expand on this study.  
 The estimated marginal means were calculated using all of the variables in the 
study: cell line, hypoxia time points, shown in the context of changes in expression of the 
genes of interest in this study (Table 10).  Additionally, the means calculated in Table 10 
comprise the data points for Figures 14-16.  In Figure 14, HIF- 1α expression was 
significantly correlated (p = .001) to the cell line in which it was expressed (U87MG versus 
MSU1.1).  Surprisingly, as discussed above with Table 5, there were no significant HIF- 1α 
expression changes evident after hypoxia exposure, except in the first three hours in a 
hypoxic culture environment (p = .215).  Additionally, the combined effects of cell line and 
hypoxic environment treatment did not elicit any statistically significant changes in HIF- 1α 
expression (p = .558) (Table 5).  The estimated marginal means of the effects of cell line, 
hypoxic exposure, and the combined effects on HIF-1 expression were analyzed in Table 
10 and then visualized in Figure 15.  HIF-1 was not significantly affected by the IV cell line 
(p = .911) but was surprisingly correlated with time spent in a hypoxic environment (p = 
.018).  The combined effects of both cell line and hypoxic exposure did not lead to 
significant changes in HIF-1 expression (p = .332) (Table 10 and Figure 15).  Overall, 
hypoxic exposure was the only variable that affected HIF-1 expression in this study, which 
was surprising and will be discussed more in depth in the following chapter.  The estimated 
marginal means of GLUT1 expression were also depicted in Table 10 and visualized in 
Figure 16.  GLUT1 expression correlated to the cell line it was expressed in (p = .000) and 
was also significantly affected by the hypoxic treatment (p = .000) and when combined 
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effects of cell line and hypoxia treatment (p = .002).  The significance of GLUT1 expression 
changes in reference to hypoxia and cell line will be discussed in the following section.  














HIF-1ɑ HIF-1β Set 1 HIF-1β Set 2
98 bp 55 bp 80 bp
 
FIGURE 6: EXPRESSION OF THE GENES HIF-1 AND HIF-1 WAS CONFIRMED IN BOTH HYPOXIA 
TREATED U87MG CELLS AS WELL AS IN U87MG CELLS THAT ONLY GREW IN A NORMOXIC 
ENVIRONMENT. 
From left to right: 50 bp DNA ladder, HIF-1 (98 bp) after hypoxic exposure (treatment), 
HIF-1 (98 bp) expression after no hypoxic exposure (control), blank lane, HIF-1 (55 bp) 
expression after hypoxic environment exposure (treatment), HIF-1 (55 bp) expression 
after no hypoxic environment exposure (control), blank lane, HIF-1 (2nd primer set- 80 
bp) expression after hypoxic environment exposure (treatment), HIF-1 (2nd primer set- 
80 bp) expression in normoxia- after no hypoxic environment exposure (control), blank 
well. 














HIF-1ɑ HIF-1β Set 1 HIF-1β Set 2
98 bp 55 bp 80 bp
 
FIGURE 7: EXPRESSION OF THE GENES HIF-2A AND HIF-2B WAS CONFIRMED IN BOTH HYPOXIA 
TREATED U87MG CELLS AS WELL AS IN U87MG CELLS THAT ONLY GREW IN A NORMOXIC 
ENVIRONMENT. HIF-3A WAS NEITHER CONFIRMED TO BE EXPRESSED IN HYPOXIA TREATED 
U87MG CELLS NOR IN CONTROL NORMOXIA TREATED U87MG CELLS. 
From left to right: 50 bp DNA ladder, HIF-2 (183 bp) after hypoxic exposure (treatment), 
HIF-2 (183 bp)expression after no hypoxic exposure (control), blank lane, HIF-2 (234 
bp) expression after hypoxic environment exposure (treatment), HIF-2 (234 bp) 
expression after no hypoxic environment exposure (control), blank lane, HIF-3 (1st 
primer set) (72 bp)expression after hypoxic environment exposure (treatment), HIF-3 
(1st primer set) (72 bp) expression after no hypoxic environment exposure (control), blank 
well.  
 






















































FIGURE 8: EXPRESSION OF THE GENES HIF-3 AND GLUT1 WAS CONFIRMED IN BOTH HYPOXIA 
TREATED U87MG CELLS AS WELL AS IN U87MG CELLS THAT ONLY GREW IN A NORMOXIC 
ENVIRONMENT. THE SECOND PRIMER SET DESIGNED FOR HIF-3 NEITHER CONFIRMED HIF-3 
EXPRESSION IN HYPOXIA TREATED U87MG CELLS NOR IN CONTROL NORMOXIA TREATED U87MG 
CELLS. 
From left to right: 50 bp DNA ladder, HIF-3 (2nd primer set) (70 bp) after hypoxic 
exposure (treatment), HIF-3 (2nd primer set)(70 bp) expression after no hypoxic 
exposure (control), blank lane, HIF-3 (177 bp) expression after hypoxic environment 
exposure (treatment), HIF-3 (177 bp) expression after no hypoxic environment exposure 
(control), blank lane, GLUT1 (231 bp) expression after hypoxic environment exposure 
(treatment), GLUT1 (231 bp) expression after no hypoxic environment exposure (control), 
blank well.  
 




























FIGURE 9: EXPRESSION OF GLUT3 WAS CONFIRMED IN BOTH HYPOXIA TREATED U87MG CELLS 
AS WELL AS IN CONTROL (NORMOXIA) U87MG CELLS.  
From left to right: 50 bp DNA ladder, GLUT3 (75 bp) after hypoxic exposure (treatment), 
GLUT3 (75 bp) in U87MG cells only exposed to normal oxygen conditions (control).  












































FIGURE 10: EXPRESSION OF HIF-1, HIF-1, HIF-2, HIF-2, HIF-3, AND GLUT1 IN 
MSU1.1 FIBROBLAST CELLS AFTER 48 HOURS OF HYPOXIA EXPOSURE.  
FROM LEFT TO RIGHT: 50 BP DNA LADDER, CONTROL LANE WITH NO TEMPLATE MSU1.1 CDNA, 
HIF-1 (98 BP), HIF-2 (183 BP), HIF-2 (234 BP), HIF-3 (177 BP), AND GLUT1 (231 BP).  
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TABLE 3: SUMMARY OF END-POINT PCR STUDY 
THE FOLLOWING TABLE DEPICTS THE RESULTS OF THE END-POINT PCR AND SUBSEQUENT GEL 
ELECTROPHORESIS OF THE GENES IN U87MG AND MSU1.1 CELLS: HIF-1Α, HIF-1 (1ST AND 2ND 
PRIMER PAIR SETS), HIF-2Α, HIF-2, HIF-3Α (1ST AND 2ND PRIMER PAIR SETS), HIF-3, 
GLUT1, AND GLUT3. 
 
Normoxia Hypoxia Normoxia Hypoxia
HIF-1a Present Present Present Present
HIF-1b Present Present Not Tested Not Tested
HIF-2a Present Present Present Present
HIF-2b Present Present Present Present
HIF-3a- 1st Primer Set Inconclusive Inconclusive Not Tested Not Tested
HIF-3a- 2nd Primer Set Inconclusive Inconclusive Not Tested Not Tested
HIF-3b Present Present Present Present
GLUT1 Present Present Present Present
GLUT3 Present Present Present Present
U87 Glioblastoma Cells  MSU1.1 Fibroblast Cells (Control Cells)









FIGURE 11: RELATIVE EXPRESSION OF HIF-1 IN U87MG CELLS AND MSU1.1 CELLS AFTER 
HYPOXIA TREATMENT. 
Relative expression level of HIF-1 had a statistically significant peak in the first 3 hours of 
hypoxic exposure treatment. The qRT-PCR results appear to show a trend in U87MG cells: 
HIF-1α levels increase over time in hypoxia and have a significant peak after 12 hours of 
hypoxia exposure. However, the trend showing a gradual increase over time, with a peak at 
12 hours that is not statistically significant. The expression levels in MSU1.1 cells are 
generally higher than in U87MG cells, but there is no trend in relation to time spent in 
hypoxia.  
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FIGURE 12: RELATIVE EXPRESSION OF HIF-1 IN U87MG CELLS AND MSU1.1 CELLS AFTER 
HYPOXIA TREATMENT. 
Two-way ANOVA was utilized for analysis of the relative fold change observed in both 
U87MG and MSU1.1 cells during a hypoxia time course assay. qRT-PCR was conducted on 
cDNA from RNA isolated from U87MG cells and MSU1.1 cells. In U87MG cells, HIF-1 levels 
increase over time in hypoxia and peak at 12 hours, but the trend is not statistically 
significant.  No distinct trend is apparent in MSU1.1 cells. There was a distinctly higher 
baseline expression of HIF-1 seen in MSU1.1 cells than in the other genes investigated in 
this study: HIF-1a in Figure 11 and GLUT1 in Figure 13.  
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FIGURE 13: RELATIVE EXPRESSION OF GLUT1 IN U87MG AND MSU1.1 CELLS AFTER HYPOXIA 
TREATMENT. 
qRT-PCR results appear to show a trend in U87MG cells: GLUT1 levels increased over time 
spent in hypoxia and peaked at 24 hours. Using MANOVA pairwise comparisons, the mRNA 
fold change levels of in U87MG and MUS1.1, that were measured at each hypoxia time point 
(3,6,12, and 24 hours), were normalized to the baseline GLUT1 mRNA expression from 
U87MG and MSU1.1 cells that were never exposed to hypoxic conditions.  
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TABLE 4: ∆CT VALUES USED FOR MANOVA MULTIVARIATE ANALYSIS 
The following chart depicts the ∆CT values determined by the StepOnePlus Thermocycler 
software. The following values were utilized for MANOVA analysis. The ∆CT was utilized 
over the ∆∆CT to keep the normoxia ∆Ct values to use as a control factor in the MANOVA 
analysis. The MANOVA results are shown in Table 4.  
Raw	Data	used	for	MANOVA	Multivariate	Analysis
Cell	Line Treatment Δ CT	HIF1a Δ CT	HIF1b Δ CT	GLUT1
U87
Normoxia 0.390237808 8.862180233 6.975073179
Normoxia 4.681705793 11.33155982 11.833498
Normoxia 4.256052971 10.21491146 12.66498693
3	Hour 0.959792773 10.76535384 8.108195623
3	Hour 3.697454453 9.111228943 8.134410222
3	Hour 3.657238324 9.22144858 10.88333511
6	Hour -1.579455058	 7.83086268 8.561536789
6	Hour 4.533393542 7.603870074 7.842486064
6	Hour 4.254323324 8.735117594 11.44408894
12	Hour 0.86288929 7.628475507 7.218052864
12	Hour 0.994344076 6.518761953 6.66847229
12	Hour 2.983535767 7.028027217 11.17832947
24	Hour 0.192746798 8.476341565 0.073177338
24	Hour 5.204382261 10.5066309 6.624696732
24	Hour 4.931388855 8.970122019 9.319644292
MSU1.1
Normoxia 3.142354965 8.140199025 5.464523315
Normoxia 5.871913433 10.85678816 11.15261587
Normoxia 4.286186854 10.8575236 10.87225914
3	Hour 2.596813202 8.067699432 4.847998301
3	Hour 2.570558548 7.713668823 9.600447973
3	Hour 3.153512319 9.428974152 7.063512166
6	Hour 2.392367045 7.469454447 5.085081418
6	Hour 3.588159243 9.148351351 8.939088821
6	Hour 4.331070582 8.967363993 9.863989512
12	Hour 3.747689565 8.277808507 4.958525976
12	Hour 3.419293086 8.271207809 9.395822525
12	Hour 1.733569463 8.984543482 10.72193146
24	Hour 3.216023127 8.594952901 4.716258367
24	Hour 3.787295659 8.864278793 9.2711188
24	Hour 5.77850914 10.09346962 8.524061203
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TABLE 5: MANOVA TESTS OF BETWEEN-SUBJECTS EFFECTS 
The MANOVA was utilized the analyze the general effect that each independent variable 
had on the group of dependent variables: HIF-1α, HIF-1, and GLUT1. However, the 
MANOVA analyzed the effects that these independent variables (cell line and hypoxia 
treatment) had on the dependent variables clumped as a group of genes. Significant effects 
were using all four of the multivariate statistical analyses: Pillai’s Trace, Wilks’s Lambda, 
Hotelling’s Trace, and Roy’s Largest Root.  P-values were all less than 0.05, which indicates 
a strongly significant effect resulting from the independent variables labeled in the first 
column of the table.  
*Statistically significant values are highlighted in the figure below.  










Pillai's Trace 0.994 975.499b 3.000 17.000 0.000 2926.498 1.000
Wilks' Lambda 0.006 975.499b 3.000 17.000 0.000 2926.498 1.000
Hotelling's Trace 172.147 975.499b 3.000 17.000 0.000 2926.498 1.000
Roy's Largest Root 172.147 975.499b 3.000 17.000 0.000 2926.498 1.000
CellLine
Pillai's Trace 0.845 30.849b 3.000 17.000 0.000 92.546 1.000
Wilks' Lambda 0.155 30.849b 3.000 17.000 0.000 92.546 1.000
Hotelling's Trace 5.444 30.849b 3.000 17.000 0.000 92.546 1.000
Roy's Largest Root 5.444 30.849b 3.000 17.000 0.000 92.546 1.000
Treatment
Pillai's Trace 1.220 3.256 12.000 57.000 0.001 39.069 0.987
Wilks' Lambda 0.154 3.872 12.000 45.269 0.000 39.124 0.982
Hotelling's Trace 3.219 4.203 12.000 47.000 0.000 50.439 0.998
Roy's Largest Root 2.363 11.227c 4.000 19.000 0.000 44.906 0.999
Cell Line * 
Treatment
Pillai's Trace 1.021 2.449 12.000 57.000 0.012 29.390 0.938
Wilks' Lambda 0.218 2.939 12.000 45.269 0.004 29.974 0.932
Hotelling's Trace 2.570 3.355 12.000 47.000 0.001 40.262 0.986
Roy's Largest Root 2.143 10.178c 4.000 19.000 0.000 40.710 0.998
a. Design: Intercept + Cell Line + Treatment + Cell Line * Treatment
b. Exact statistic
c. The statistic is an upper bound on F that yields a lower bound on the significance level.
d. Computed using alpha = .05  
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TABLE 6: TEST OF BETWEEN-SUBJECTS EFFECTS SHOWN FOR EACH GENE OF INTEREST 
Univariate ANOVAs were performed after the MANOVA to determine whether the 
independent variables (cell line, in-vitro hypoxic exposure, and the combined effects from 
the two variables) influenced the expression of the each of the dependent variables (HIF-
1α, HIF-1, and GLUT1), when viewed autonomously from the other genes.  The univariate 
tests concluded that cell line had a significant effect on the individual expression levels of 
HIF-1α (p = .001) and GLUT1 (p = .000), but not on HIF-1. In-vitro hypoxia exposure had a 
significant effect on the individual expression of HIF-1 (p = .018) and GLUT1 (p =.000) and 
surprisingly not on HIF-1α (p = .215), which is surprising since it is considered mainstream 
that HIF-1 α is successfully activated by a hypoxic environment. Then the effects of both 
independent variables were combined to determine their mutual effect on each gene’s 
expression level; when combined these two factors had a significant effect on GLUT1 
expression (p = .002).  
*Statistically significant values are bolded in the figure below.  
Tests of Between-Subjects Effects
Source











HIF1a Log 3.480a 9 0.387 2.618 0.037 23.565 0.803
HIF1b Log 1.734b 9 0.193 2.272 0.063 20.452 0.733
GLUT1 Log 75.899c 9 8.433 13.708 0.000 123.375 1.000
Intercept
HIF1a Log 19.375 1 19.375 131.204 0.000 131.204 1.000
HIF1b Log 211.273 1 211.273 2491.413 0.000 2491.413 1.000
GLUT1 Log 50.621 1 50.621 82.285 0.000 82.285 1.000
Cell Line
HIF1a Log 2.140 1 2.140 14.495 0.001* 14.495 0.950
HIF1b Log 0.001 1 0.001 0.013 0.911 0.013 0.051
GLUT1 Log 37.322 1 37.322 60.668 0.000* 60.668 1.000
Treatment
HIF1a Log 0.947 4 0.237 1.603 0.215 6.410 0.399
HIF1b Log 1.311 4 0.328 3.864 0.018* 15.454 0.805
GLUT1 Log 23.540 4 5.885 9.566 0.000* 38.264 0.997
CellLine * 
Treatment
HIF1a Log 0.455 4 0.114 0.770 0.558 3.081 0.202
HIF1b Log 0.417 4 0.104 1.228 0.332 4.913 0.310
GLUT1 Log 14.993 4 3.748 6.093 0.002* 24.371 0.954
Error
HIF1a Log 2.806 19 0.148
HIF1b Log 1.611 19 0.085
GLUT1 Log 11.689 19 0.615
Total
HIF1a Log 25.660 29
HIF1b Log 214.618 29
GLUT1 Log 138.208 29
Corrected Total
HIF1a Log 6.285 28
HIF1b Log 3.346 28
GLUT1 Log 87.587 28
a. R Squared = .554 (Adjusted R Squared = .342)
b. R Squared = .518 (Adjusted R Squared = .290)
c. R Squared = .867 (Adjusted R Squared = .803)
d. Computed using alpha = .05  
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TABLE 7: PAIRWISE COMPARISONS OF VARIOUS TIME POINTS IN HYPOXIC ENVIRONMENT AND 
EFFECTS SEEN IN THE EXPRESSION OF HIF-1Α CONDUCTED BY MULTIPLE UNIVARIATE ANOVA. 
The following table depicts the results of multiple univariate ANOVAs that were conducted 
to determine the effects that each hypoxia exposure time point had on the expression of 
HIF-1α. This chart does not include any effects from cell line, only the effects of hypoxia 
exposure treatment. Between 0-3 hours of hypoxia, there was a significant change in the 
relative expression of HIF-1α.  
*Statistically significant values are highlighted and bolded in the figure below.  
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TABLE 8: PAIRWISE COMPARISONS OF THE EXPRESSION LEVELS OF HIF-1 AT EACH HYPOXIA TIME 
POINT CONDUCTED BY MULTIPLE UNIVARIATE ANOVA ANALYSIS 
The following table depicts the effects that the hypoxia exposure time point had on the 
expression of HIF-1. This chart does not include any effects from cell line, only the effects 
resulting from hypoxic exposure treatment. Between the following time periods there were 
significant changes in the expression of HIF-1: 0-6 hours, 0-12 hours, 12-24 hours in 
hypoxia.  
*Statistically significant values are highlighted and bolded in the figure below.  
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TABLE 9: MULTIVARIATE ANALYSIS PAIRWISE COMPARISONS OF THE EXPRESSION LEVELS OF 
GLUT1 AT EACH HYPOXIA TIME POINT CONDUCTED BY MULTIPLE UNIVARIATE ANOVA 
The following table depicts the effects that the hypoxia exposure time point had on the 
expression of GLUT1. This chart does not include any effects from cell line, only the effects 
resulting from hypoxic exposure treatment. Between the following time periods there were 
significant changes in the expression of GLUT1: 0-3 hours, 0-6 hours, 0-12 hours, and 0-24 
hours in hypoxia.  
*Statistically significant values are highlighted in the figure below.  
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TABLE 10: MULTIPLE UNIVARIATE ANOVA PAIRWISE COMPARISONS OF EXPRESSION LEVELS OF 
HIF-1, HIF-1 AND GLUT1 IN U87MG CELLS AND MSU1.1 CELL LINES.  
The following table depicts the significance of the effects seen in the individual gene 
expression levels of HIF-1α, HIF-1, and GLUT1. Each gene was analyzed separately along 
with a concordant independent variable, cell line. Below it shows that HIF-1α expression is 
significantly different in the two cell lines and it is visualized in Figures 11 and 14.  In this 
analysis, HIF-1 expression was not significantly affected by cell line, which was also found 
in the multiple univariate ANOVAs depicted in Table 5. GLUT1 expression was significantly 
affected by the cell line it was being expressed in, which was also shown in Table 5.  
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TABLE 11: ESTIMATED MARGINAL MEANS OF HIF-1Α, HIF-1, AND GLUT1 IN BOTH U87MG 
AND MSU1.1 CELL LINES 
The following table shows the estimated marginal means of the measured effects that each 
cell line and hypoxia time point have on the gene being expressed (HIF-1α, HIF-1, and 
GLUT1). These values are visualized in Figures 14-16 and their significance is discussed 
above in the results section.  
  







FIGURE 14: MULTIVARIATE ANALYSIS ESTIMATED MARGINAL MEANS PLOT DEPICTING HOW CELL 
LINE IS SIGNIFICANTLY CORRELATED TO HIF-1A RELATIVE EXPRESSION LEVEL CHANGES. 
This chart illustrates the statistical analysis data shown in Table 10. Overall, HIF-1 
expression was significantly correlated to the cell line it was expressed in: U87MG versus 
MSU1.1 (p = .001). However, the hypoxia treatment did not lead to significant changes in 
HIF-1 expression (p = .215) and there was no significance when the effects of cell line and 
hypoxia treatment were combined during statistical analysis (p = .558).  









FIGURE 15: MULTIVARIATE ANALYSIS ESTIMATED MARGINAL MEANS PLOT DEPICTING HOW 
HYPOXIA EXPOSURE OVER TIME LEADS TO HIF-1B RELATIVE EXPRESSION LEVEL CHANGES IN BOTH 
U87MG CELLS AND MSU1.1 CELLS. 
This chart illustrates the data shown in Table 10. Overall, HIF-1 expression was not 
significantly correlated to the cell line it was expressed in: U87MG versus MSU1.1 (p = 
.911). However, HIF-1 expression was significantly correlated with hypoxia treatment (p 
= .018). When the effects of cell line and hypoxia treatment were combined during 
statistical analysis, the interaction was not significant (p = .332). Overall, hypoxia treatment 
significantly affected HIF-1 expression.   
 










FIGURE 16: MULTIVARIATE ANALYSIS ESTIMATED MARGINAL MEANS PLOT DEPICTING HOW 
HYPOXIA EXPOSURE OVER TIME LEADS TO GLUT1 RELATIVE EXPRESSION LEVEL CHANGES. 
This chart illustrates the data shown in Table 10. Overall, GLUT1 expression was 
significantly correlated to the cell line it was expressed in: U87MG versus MSU1.1 (p = 
.000). GLUT1 was also significantly correlated with hypoxia treatment (p = .000). When the 
interacting effects of cell line and hypoxia treatment were combined during statistical 
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The aim of this study was to determine whether hypoxia has a role in regulating the 
expression of HIF-1, HIF-1, and GLUT1 in a GBM cancer cell line. We hypothesized that 
the expression of these genes is proportional to in-vitro hypoxic conditions.  The in-vitro 
model consisted of the U87MG (GBM) cell line as well as MSU1.1 (fibroblast) cell line and 
relative gene expressions of HIF-1, HIF-1, and GLUT1 were characterized in these lines.  
Although MSU1.1 cells were used as a control and therefore not the focal point of the study, 
the limited number of studies characterizing MSU1.1 cells make findings from this study 
potentially novel.  Contrastingly, the expressions of HIF-1, HIF-1, and GLUT1 as well as 
the direct relationship that HIF-1 and HIF-1 expression have on downstream targets 
such as GLUT1, have been well characterized in many studies. However, the relationship of 
acute versus chronic hypoxia on the expression of these genes has not been fully 
elucidated.   
There appear to be two factors modulating HIF differential regulation: the severity 
of the hypoxic environment and time spent in hypoxia (acute versus chronic).  It appears 
that HIF-1 expression is more responsive to severe hypoxia (1-3% O2) than the other HIF 
proteins, primarily HIF-2, whose expression has been characterized in less hypoxic 
conditions (5% O2) (Holmquist-Mengelbier et al., 2006). Additionally, it has been 
postulated that HIF-2 rather than HIF-1 mediates responses to chronic hypoxia (12+ 
hours), while HIF-1 only mediates responses to acute episodes of hypoxia.  In two 
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neuroblastoma cell lines grown in 1% O2, expression of HIF-1 climbed rapidly in the first 
couple of hours in hypoxia, but then gradually decreased after 72 hours.  Contrastingly, 
HIF-2 protein expression consistently climbed in 1% O2 for all 72 hours of the study.  
When taken together it suggests that HIF-2 and not HIF-1 is likely responsible for 
changes in chronically hypoxic areas at physiological O2 levels, at least in a neuroblastoma 
model (Holmquist-Mengelbier et al., 2006).   
It is worth noting that in the aforementioned neuroblastoma model, HIF-2 mRNA 
levels increased in both 1% and 5% O2 conditions despite a concurrent rise in PHD2 and 
PHD3 protein levels, whose role is to inactivate HIFs.  This data suggests that HIF-2 grows 
less sensitive to PHDs over time or that high protein synthesis of HIF-2 can counteract 
PHD degradation (Holmquist-Mengelbier et al., 2006).  With this study in mind, it is a good 
reminder that any relative expression changes noted in this study could be due to a 
decreased sensitivity to other protein regulators rather than simply being upregulated.  
Acute versus chronic hypoxia in the context of HIF-1 versus HIF-2 expression was not 
investigated in this study, aside from the confirmed presence of HIF-2, HIF-2, and HIF-3 
were confirmed in U87MG and MSU1.1 cells in both normoxia and hypoxia using end-point 
PCR.  Further studies investigating the relative expression levels of the various HIFs in 
various tissues needs to be done. A particularly underdeveloped area of HIF research is 
regarding the temporal differences  of the HIFs as well as their general sensitivity to O2 
conditions (Holmquist-Mengelbier et al., 2006) in the tumor microenvironment and in 
normal tissues.  However, studies on the genes downstream of HIFs, such as GLUT1, are 
needed to understand the GBM microenvironment at the various proximities to 
vasculature.  
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This study aimed to confirm that HIF-1, HIF-1, and GLUT1 are all expressed in 
U87MG cells, using the largely uncharacterized MSU1.1 fibroblast cells as a ‘novel’ control 
cell line.  The expression of HIF-1, HIF-1, HIF-2, HIF-2, HIF-3, GLUT1, and GLUT3 
were confirmed in U87MG and MSU1.1 cells (Figures 6-10). However, the presence of HIF-
3 in either cell line was not successfully characterized in this study, very likely due to 
primer design issues.  It is possible that the primer could be effective, but that the 
conditions needed to induce expression of HIF-3 might not have been ideal in the design 
of this study. However, that is unlikely since ‘moderate’ hypoxia has been shown to induce 
the expression of some HIF-3 variants (Heidbreder et al., 2003).  To test this in an in-vitro 
model, cells could be exposed to 1% and 5% O2 levels for time periods spanning a few 
minutes to 72 hours could elucidate more about HIF-3 relative expression.  
The NCBI Gene Database and Blast were utilized to design the primers and used to 
test the sequences of HIF-3 primers that were used in past studies.  Upon researching, it 
was discovered that many of the published HIF-3 primer sequences did not successfully 
target HIF-3 when analyzed.  Therefore, the characterization of HIF-3 published thus far 
might be more inconclusive than thought prior to this study.  Due to the issues designing a 
suitable HIF-3 primer in this study and or its lack of expression and amplification, its 
characterization was not continued after the EP-PCR phase of this study.  However, it 
remains a highly contentious aspect of hypoxia medicated expression changes in GBM.  
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G e n e r a l  E f f e c t s  o f  C e l l  L i n e  a n d  H y p o x i c  E x p o s u r e  T r e a t m e n t  o n  
L u m p e d  E x p r e s s i o n  o f  H I F - 1 ,  H I F - 1 ,  a n d  G L U T 1  
 
 
The qPCR data acquired only investigated the expression of HIF-1, HIF-1, and 
GLUT1.  As mentioned previously, (p. 43, 49-50), two types of statistical analyses were 
conducted: MANOVA and multiple Two-way ANOVAs. MANOVA was conducted to 
determine the general effect that each independent variable (IV) or the interaction of the 
two IVs (Cell line and hypoxia exposure), had on the expression of all the following genes 
lumped together: HIF-1, HIF-1, and GLUT1 (Table 4). These results show that cell line, 
hypoxic exposure, and the interaction of the two factors each independently led to 
significant general effects in the expression of the group of target genes (HIF-1, HIF-1, 
and GLUT1) and are shown in Table 4. Since a general effect from the cell lines and hypoxic 
treatment had significant effects in gene expression, additional statistical tests were 
conducted to determine the effects that each IV had on the expression of each individual 
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S p e c i f i c  E f f e c t s  o f  C e l l  L i n e  a n d  H y p o x i c  E x p o s u r e  T r e a t m e n t  o n  
G e n e  E x p r e s s i o n  
 
 
E f f e c t  o f  C e l l  T y p e  o n  I n d i v i d u a l  G e n e s  E x p r e s s e d  
 
 
Multiple two-way ANOVAs identified significant correlations between cell type and 
each of the following genes (DVs): HIF-1 and GLUT1.  It was expected that both genes 
would be upregulated in the U87MG GBM cells compared to the MSU1.1 cells since GLUT1 
has been shown to be overexpressed in cancerous tissues, including GBM (Ma et al., 2015) 
(J. Liu et al., 2015) (Asmaa Gaber Abdou, MD et al., 2015) (Labak et al., 2016) (Nes, 
Johannes AP, et al, 2015) (Bache et al., 2015).  GLUT1 is a downstream target gene of HIF-1, 
but not solely of HIF-1α and is over-expressed in cancerous tissues, whether resulting from 
hypoxia or oncogenic activation, or can just result from hypoxic normal tissues. In this 
study, the differential expression of HIF-1α in the two cell lines was higher in GBM cells 
than in the control MSU1.1 fibroblasts used in this study, which aligns with the general 
knowledge of the field.   The lack of effect seen in HIF-1 was surprising because of its 
concordant expression with HIF-1, which is upregulated in many tissues and in malignant 
tumors.   Therefore, U87MG and MSU1.1 fibroblast cells likely have differential signaling of 
hypoxia induced HIF-1 stability and the downstream GLUT1 upregulation.  More 
specifically, other HIFs could be at play in this scenario, such as HIF-2, and this requires 
future study to better understand this phenomenon.  
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E f f e c t  o f  H y p o x i a  E x p o s u r e  T r e a t m e n t  o n  I n d i v i d u a l  G e n e s  E x p r e s s e d  
 
 
Two-way ANOVA also found that hypoxia exposure treatment affected HIF-1 and 
GLUT1 expression, but surprisingly not HIF-1 expression except within the first three 
hours of hypoxic exposure. It was expected that GLUT1 would be responsive to relative 
oxygen levels as well as to the cell line in which it was expressed.  Many studies have 
reported that GLUT1 is enriched in areas of the brain, especially in endothelial cells lining 
the blood brain barrier.  Since GLUT1 is upregulated in healthy brain tissues, it isn’t 
surprising that GLUT1 is overexpressed in GBM cells since they occur in the brain.  This 
upregulation of GLUT1 seen is adaptive in light of the Warburg Effect.   Studies have shown 
that cancer cells display a tendency to metabolize glucose more than normal cells.  Cancer 
cells perform aerobic glycolysis as their main method of ATP generation rather than using 
mitochondrial respiration.   
It was expected that HIF-1α would be responsive to hypoxia treatment in the first 
few hours of the assay, which was seen in this study in the first three hours of hypoxic 
exposure (G. L. Wang, Jiang, Rue, & Semenza, 1995).  HIF-1 expression has been shown to 
be dependent on relative oxygen concentration, but there are some reports that HIF-1 is 
only present by acute hypoxia which could explain why it was overexpressed in the first 
three hours as opposed to after 24 hours of hypoxic exposure. As discussed, the PHD 
enzymes that regulate HIF stability are not active during hypoxia, but eventually stabilize in 
chronic hypoxia and then start to again degrade HIF-1 proteins quickly as they do in 
normoxia. However, if this post-translational HIF-1 protein degradation is occurring, it is 
possible that HIF-2 protein might be elevated in the (5% O2) experimental conditions of 
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this study, but the expression of HIF-2 likely wouldn’t have been activated until the 
relative oxygen was decreased further to around 3% O2. Regardless, it does not account for 
why the transcription of HIF-1 is only increased within the first three hours of hypoxic 




I n t e r a c t i o n  E f f e c t  o f  C e l l  T y p e  a n d  H y p o x i a  E x p o s u r e  T r e a t m e n t  o n  
I n d i v i d u a l  G e n e s  E x p r e s s e d  
 
Analysis using two-way ANOVA found that GLUT1 expression was significantly 
affected when both cell line and hypoxia exposure were used as factors (Table 4).  
Specifically, hypoxic exposure led to a significant upregulation of HIF-1 (Figure 12) and 
GLUT1 transcription (Figure 13) in U87MG (GBM) cells compared to control MSU1.1 
fibroblast cells.  These results led us to reject the null hypothesis that GLUT1 and HIF-1 
expression changes are directly correlated with in-vitro hypoxic conditions because there 
were significant changes seen in the genes of interest due to hypoxic exposure as well as 
between cell lines.  The upregulation of HIF-1 was surprising because numerous other 
studies have shown that HIF-1 is constitutively made and requires the hypoxia dependent 
HIF-1 subunit to elicit any changes to the cell. Without HIF-1α hetero-dimerization with 
the HIF-1 subunit, there is no translocation into the nucleus and no HIF initiated genetic 
changes within the host cell.   
As could be expected based on the above reasoning, the combined effects of cell line 
and hypoxia exposure led to a significant interactional effect in GLUT1 expression. It was 
expected that GLUT1 would be responsive to relative oxygen levels as well as to the cell 
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line in which it was expressed. Many studies have reported that GLUT1 is enriched in areas 
of the brain, especially in endothelial cells lining the blood brain barrier (Zuchero et al., 
2016). The Warburg Effect also hypothesized that cancer cells tend to metabolize glucose 
more than normal cells.  Cancer cells perform aerobic glycolysis as their main method of 
ATP generation rather than using mitochondrial respiration. Therefore, the upregulation of 
GLUT1 in U87MG cells compared to MSU1.1 cells in this study is characteristic of typical 




P o t e n t i a l  E f f e c t  o f  C h r o n i c  v e r s u s  A c u t e  H y p o x i a  
 
 
Perhaps the stabilization of HIF-1α is more easily accomplished in malignant cells 
than in healthy cells. This could be accomplished by altering the various mechanisms by 
which HIF-1α is normally degraded. As there are multiple pathways that can degrade HIFs, 
it is possible that some of the hypoxia regulating signaling cascades are specific to cell type 
and malignancy status, as well as to the specific level of oxygen in the tumor 
microenvironment.  Several studies have suggested that there are also differences in HIF 
family expression levels based on the percentage of oxygen in the environment (Holmquist-
Mengelbier et al., 2006).  Some would argue that the 5% O2 used in this study wasn’t low 
enough and would have recommended 1% O2 or lower to stabilize HIF-1α.  
Since the longest hypoxia time point in this study was 24 hours, a larger sample size 
and longer treatment times might be needed to get a comprehensive understanding of HIF-
1α/ expression and regulation. A larger number of biological replicates as well as more 
technical replicates would help to yield a more comprehensive understanding of this 
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phenomenon. Overall, this study found that HIF-1 and GLUT1 were responsive to changes 




S u m m a r y  
 
 
Hypoxia has been shown to lead to GLUT1 upregulation in various cancer types including: 
endometrial (Ma et al., 2015), gastric (J. Liu et al., 2015), squamous cell carcinoma (Asmaa 
Gaber Abdou, MD et al., 2015), ovarian (Labak et al., 2016), meningioma (Nes, Johannes AP, 
et al, 2015), and glioblastoma (Bache et al., 2015) and has been implicated in metabolic 
remodeling, which is one of the hallmarks of cancer. The positive correlation of GLUT1 and 
HIF-1 with an acutely hypoxic GBM microenvironment has been described in this study in 
a GBM and fibroblast cell line model. This   provides further confirmation that these two 
proteins are interrelated.  However, this is needs to be investigated further, as the hypoxia 
severity was not directly tested. Additionally, GLUT1 is also upregulated in normal tissues 
including the cortex, hippocampus, and the liver after short periods (2 hours) of hypoxia 
(Heidbreder et al., 2003). Its upregulation has been induced by oncogenic transformation 
(C. Chen et al., 2001, p. 9519) as well as by hypoxic conditions modulated by HIF-1 
expression.  The presence of GLUT1 in GBMs and other tumors makes it a fair candidate for 
cancer therapies, but systemic treatments targeting GLUT1 might be detrimental due to the 
to its widespread distribution throughout the body, especially in the brain (Denko, 
2008)(Ozbudak et al., 2008)(Airley & Mobasheri, 2007).  
However, GLUT3 has been shown to be hypoxia modulated via HIF-1 as well (Y. Liu 
et al., 2009a)(Rooj et al., 2016), and may be a better target for cancer therapies, as both 
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GLUT1 and GLUT3 have been shown to have increased expression in the hypoxic tumor 
microenvironment (Y. Liu et al., 2009a) and CSC self-renewal (Christensen et al., 2015, p. 
4).  By extension, the HIF-modulated tumor microenvironment selects for the intra-tumoral 
CSC population which is thought to indirectly confer a myriad of selective advantages to the 
tumor such as tumor aggression, resistance to treatment, tumor recurrence, and invasion 
of other tissues (Labak et al., 2016).  Additionally, differences in glycolytic metabolism have 
been found in CSC populations (Zhou et al., 2011)(Hanahan & Weinberg, 2011) which 
further supports the argument that CSCs, the GBM microenvironment, and metabolic 
remodeling are interrelated.  A study confirmed that GLUT3 was expressed more in highly 
malignant gliomas as opposed to low-grade gliomas, and since it was the predominant 
GLUT in the tumor it was a good prognostic factor for patients (Y. Liu et al., 2009a).  Despite 
the need to study GLUT3, its relative expression was not measured in this study due to time 
and budget constraints.   
The direct relationship of GLUT1 and GLUT3 and their roles in GSCs are still 
debated, but they appear to be very good targets for the GSC population in the GBM(Y. Liu 
et al., 2009a)(Shibuya et al., 2015). Specifically, in mice, GLUT1 was identified as a major 
protein in the blood brain barrier (Zuchero et al., 2016) and as the blood brain barrier is an 
obstacle to drug treatment, GLUT1 being highly expressed could help identify future 
mechanisms to treat GBM and other CNS malignancies.  As both GLUTs 1 and 3 have been 
found within GBM (Y. Liu et al., 2009b), it seems that there is a likely correlation with 
tumor grade, intra-tumor cell populations, and potentially the level of hypoxia and thus 
HIF-1 versus HIF-2 regulation. Exclusively HIF-2 and not HIF-1 has been shown to 
regulate Oct4 expression by binding to the Oct4 promoter depicted in a mouse embryo in-
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vivo model (Covello et al., 2006, p. 4). These studies that have found HIF-2 regulates Oct4 
indicates that HIF-2 is related to the stem cell subpopulation of the GBM that has been 
shown to confer treatment resistance. However, knockdown of HIF-1 expression has been 
linked with abrogation in CD-133 positive GSCs, which indicates also that HIF-1 has a role 
with stem cells in GBM.   This finding could prove useful, as it answers another question 
about which proteins modulate GSCs and consequently tumor aggression, immune 
suppression, and tumor recurrence.  Overall, the roles of HIF-1, HIF-2, GLUT1, and 
GLUT3 are still unclear, especially in clarifying which of these proteins plays a major role in 
the GSC population in glioma. It is evident that hypoxia mediates the roles of them all, at 
least indirectly, and that they play roles in many of the properties that make GBM difficult 




F u t u r e  S t u d i e s  
 
 
Additional studies would need to be conducted to further validate the data found in this 
study but confirmed our overall hypothesis: hypoxia induced changes in the genes of 
interest when viewed as a group. However, when studied individually, the patterns found 
in this study are somewhat different than the literature has described, necessitating an 
expansion of the scope of the experimental design.  Future studies should include healthy 
non-cancerous control cells, GSGs, normal neural stem cells, more varied in-vitro relative 
oxygen levels (<5%O2), and shorter (30 seconds) and longer time periods (24-48 hours) to 
analyze the mRNA expression and protein expression of these genes.  There is significant 
data from this study and others warranting continued studies of the relationship between 
  91 
the HIFs and GLUT1 using an in-vitro GBM model.  Although, budget and time constraints 
didn’t allow for exploration into GLUT-3, HIF-2, HIF-2, HIF-3 or HIF-3 expression and 
regulation, they all seem to be very interesting targets to study for future therapeutic 
approaches to GBM.  Specifically, future studies could determine the protein levels of the 
HIFs as well as the GLUTs in a GBM model with the goal of then pursuing in-vivo studies.  
Specifically, the differential regulatory roles of HIF-2 and HIF-3 in a GBM model: and 
especially in the subpopulations of the GBM.  HIF-2 would likely be a very interesting target 
to investigate and an experimental design like used in this study could be utilized.  It would 
also be worth also investigating how 1% hypoxia induced regulation differs from 5% 
oxygen, especially when applied to the role of CSCs in the GBM model.  Additionally, 
expanding this study to examine actual protein levels of these genes rather than just the 
relative expression level via mRNA expression, would be very important.  Since these genes 
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A P P E N D I X :  P R O T O C O L S  F O R  R N A  I S O L A T I O N ,  F I R S T  S T R A N D  C D N A  
S Y N T H E S I S  A N D  Q P C R  
 
M e t h o d s  
 
 





Cells were lysed directly in the cell culture dish to prevent any reversal of possible 
gene expression changes induced by the treatment conditions. As it is still contested 
whether brief normoxia exposure is long enough to reverse hypoxia induced gene 
expression changes, this precaution was taken. Cell cultures had the media aspirated and 
were then washed with 2-3 mL of cell culture grade 1xPBS.  
 
 





A mixture of the Qiagen RLT buffer and a 1:1000 -Mercaptoethanol was added to 
the cell culture dish to lyse the cells. In preparation, the RLT--Mercaptoethanol aliquots 
were housed in tin foil covered microcentrifuge tubes to minimize light induced 
degradation. 606 L of the RLT mixture was added to each culture dish. The cells were 
scraped to one side of the cell culture dish using a cell scraper. The lysate was transferred 
to a QiaShredder and was centrifuged for two minutes. This was repeated until all the 
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lysate had gone through the column. 606 L of 70% Ethanol was added to the lysate in the 
bottom of the QiaShredder tube and was mixed well by pipetting. Of this mixture, 700 L at 
a time was transferred to an RNeasy spin column and was centrifuged for 15 seconds at 
8000xg. The flow through was discarded and this was repeated until all the homogenized 
lysate had gone through the RNeasy spin column.  
 
 





700 L of the Qiagen RW1 buffer was added to the RNeasy spin column and the 
column was spun for 15 seconds at 8000xg before discarding the column flow through. 500 
L of Qiagen RPE was added to the column and was spun for 15 seconds at 8000xg before 
discarding the flow through. An additional 500 L of the RPE buffer was added and the 
column was spun down for 2 minutes at 8000xg and the flow through was discarded. The 
column was transferred to a new collection tube and was spun for 1 minute at 8000xg. The 
column was switch to another tube and then 10-20L of RNAse free water was added to 
the column. The column rested for 1 minute and was then spun for 1 minute to elute the 
RNA from the spin column. To increase the yield of RNA eluted from the column, the eluted 
RNA at the bottom of the column was pipetted and added to the top of the column again to 
get more RNA from the column. The 1 minute rest and spin were both repeated. The final 
eluent was pipetted into a microcentrifuge tube and was immediately transferred to -80C 
freezer until first strand cDNA synthesis was conducted.  
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RNA concentration was determined using the ThermoScientific Nanodrop 2000c. The RNA 
was then converted to cDNA via reverse transcription. Reverse transcription was 
conducted on the isolated RNA using either the avian myeloblastosis virus reverse 
transcriptase (AMV-RT) and the protocol suggested by the manufacturer (Promega, Cat # 
M5108) or the ThermoFisher Maxima Reverse Transcriptase (Cat # EP0741). The Promega 
protocol was utilized in reverse transcribing the RNA that was used in the End-Point PCR 
experiments. The ThermoFisher Maxima Reverse Transcriptase was used to make the 
cDNA for the qPCR experiments. The switch to the Maxima reverse transcriptase reagent 
was done due to increased efficiency and cost reduction.  
 
 





1.0 g of Oligo (dT)15 primer was added to 2 g of RNA in a microcentrifuge tube and the 
volume of water present did not exceed 11 L. The tube was heated at 70C for 5 minutes 
and were then chilled on ice for 5 minutes. The tube was briefly centrifuged in the MyFuge 
12 Mini Centrifuge (Cat# 681725) to collect all the solution at the bottom of the tube.  
The following components were added in the following order:   
  5µl AMV Reverse Transcriptase 5X Reaction Buffer (Cat# M5108) 
2.5µl dNTP mix (Cat# U1511) 
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AMV RT 30 units (Cat# M5108) 
Nuclease-Free Water to final volume 25µl 
 
The tube was mixed by gently flicking the tube. If needed, the tube was briefly centrifuged 
again to ensure that all the solution was at the bottom of the tube. The tube was incubated 
for 60 minutes at 42C. The tubes were stored at -20C for the duration of the End-Point 
PCR studies.  
  
 





All reagents were centrifuged briefly in the MyFuge (Cat# Z681725) and kept on ice for the 
duration of the protocol. The following components were added to a sterile micro-
centrifuge tube on ice in the following order:  
2 g of template RNA 
  1.0 L of (100 pmol) of oligo(dT)15 primers (Cat# C1101) 
  1.0 L of (10 mmol) dNTP Mix (Cat# U1511) 
  10.5 L Nuclease-free water (Cat# EP0741) 
 
The following reaction components were then added in the following order:  
   
  4 L 5x Maxima RT Buffer (Cat# EP0741) 
  0.5 L Nuclease-free water (Cat# EP0741)  
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*when RNAse inhibitor was not available 
  1.0 L Maxima Reverse Transcriptase (Cat# EP0741) 
 
The total volume of the reaction was 20 L. The mixture was centrifuged briefly and 
immediately placed in the programmed Bio-Rad T100 Thermal Cycler. The reactions 
incubated for 30 minutes at 50C. The reaction was terminated by heating the tubes to 
85C for 5 minutes. The cDNA product was stored in the -20C freezer for the duration of 
the qPCR studies. 
 
 
 
 
 
 
